Clinical Policy Bulletin: Erythropoiesis Stimulating Agents...More recently, the FDA (2011)...
Transcript of Clinical Policy Bulletin: Erythropoiesis Stimulating Agents...More recently, the FDA (2011)...
Erythropoiesis Stimulating Agents Page 1 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
Clinical Policy Bulletin: Erythropoiesis Stimulating Agents
Revised April 2014
Number: 0195 Policy
I. Aetna considers erythropoietin therapy (e.g., EPO, Epogen [epoetin alfa], epoetin beta, Procrit, r-HuEPO) and
darbepoietin alfa therapy (Aranesp) medically necessary when any of the following selection criteria is met
(see Appendix for specific criteria):
A. Anemia from myelodysplastic syndrome; or
B. Anemia of prematurity; or
C. Special circumstance members who will not or cannot receive whole blood or
components as replacement for traumatic or surgical loss; or
D. Treatment of anemic members scheduled to undergo high-risk surgery who are
at increased risk of or intolerant to transfusions; or
E. Treatment of anemia associated with chronic renal failure, whether or not on
dialysis; or
F. Treatment of anemia in members receiving chemotherapy for hepatitis C; or
G. Treatment of anemia of chronic disease other than cancer when an underlying
chronic disease associated with anemia has been identified (see Appendix); or
H. Treatment of anemia secondary to myelosuppressive anticancer chemotherapy
in solid tumors, multiple myeloma, lymphomas and lymphocytic leukemia; or
I. Treatment of anemia due to zidovudine in HIV-infected members.
II. Adults who are on dialysis due to chronic kidney disease (see appendix for specific criteria).
III. Aetna considers sodium ferric gluconate complex in sucrose injection (Ferrlecit) medically necessary when used as a first line treatment of iron deficiency anemia in members undergoing chronichemodialysis who are receiving supplemental erythropoietin or darbepoetin therapy.
IV.
Erythropoiesis Stimulating Agents Page 2 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
Aetna considers erythropoiesis stimulating agents experimental and investigational for all other
indications, including the following conditions, because its use in these
situations is not supported by the peer-reviewed medical literature (not an all-inclusive
list):
Acute renal injury
Anemia associated only with radiotherapy
Anemia associated with the treatment of acute and chronic myelogenous leukemia
(AML, CML) or erythroid cancers
Anemia due to bleeding (other than indications I.D. (high-risk surgery [e.g.,
colectomy, hip replacement, and knee replacement]) and I.C. (special
circumstance members) above)
Anemia due to cancer treatment in persons with uncontrolled hypertension
Anemia due to folate deficiency, B-12 deficiency, iron deficiency, hemolysis, or
bone marrow fibrosis
Anemia in Castleman's disease
Anemia in Gaucher's disease
Anemia in paroxysmal nocturnal hemoglobinuria (PNH)
Anemia in persons with erythropoietin-type resistance due to neutralizing
antibodies
Anemia of cancer not due to cancer treatment
Aplastic anemia
Autonomic dysfunction
Cardiogenic shock-associated anemia
Cerebral hypoxia/ischemia
Cognitive decline in persons with schizophrenia
Congestive heart failure
Ehlers Danlos syndrome
Guillain-Barre syndrome
Heart failure
Hemolytic anemia
Immediate correction of severe anemia
Ischemic heart disease
Multiple sclerosis
Myelofibrosis
Myocardial infarction
Physiologic anemia of pregnancy
Postural tachycardia syndrome
Prophylactic use to prevent anticancer chemotherapy-induced anemia
Prophylactic use to prevent tumor hypoxia
Scoliosis surgery
Sepsis-associated anemia
Sickle cell anemia
Stroke/subarachnoid hemorrhage (except for I.G above)
Thrombocythemia
Traumatic brain injury.
Erythropoiesis Stimulating Agents Page 3 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
Background
Erythropoietin therapy (e.g., EPO, Epogen [epoetin alfa], epoetin beta, Omontys
(peginesatide), Procrit, r-HuEPO) is used to stimulate red blood cell (RBC) production in the
bone marrow, thereby correcting anemia, minimizing the need for transfusion requirements,
and improving the quality of life for patients.
Prior to initiation of therapy, the patient's iron stores, including transferrin saturation and
serum ferritin, should be evaluated. According to the literature, transferrin saturation should
be at least 20 % and ferritin at least 100 ng/ml. In addition, since ferritin is an acute phase
reactant, it may be falsely elevated (to the normal range) in iron deficient dialysis patients.
Therefore, the best guide for iron supplementation in this group of patients is an iron
saturation greater than 20 %.
In addition, the patient should have adequate serum folate levels (3.6 to 20 ng/dl) and normal
Vitamin B12 levels (reference range varies and must be provided).
According to the the United States Food and Drug Administration (FDA)-approved labeling of
Procrit, the initial recommended dose of erythropoietin for anemia due to cancer
chemotherapy in adults is 150 units/kg 3 times per week, or 40,000 units weekly. For
pediatric patients, a starting dose of 600 Units/kg (maximum 40,000 units) is recommended.
The labeling recommends reducing the dose by 25 % when the hemoglobin approaches
12g/dL, or the hemoglobin increases by more than 1 g/dL in any 2-week period. The labeling
recommends that the dose be withheld if the patient's hemoglobin exceeds 12 g/dL, until the
hemoglobin falls below 11 g/dL, at which point the dose should then be restarted at 25 %
below the previous dose. For persons receiving erythropoietin 3 times per week, the labeling
recommends that the dose of erythropoietin be increased to 300 units/kg 3 times per week if
the response is not satisfactory (i.e., there is no reduction in transfusion requirements or a
rise in hemoglobin) after 8 weeks to achieve and maintain the lowest hemoglobin level
sufficient to avoid the need for transfusions and not to exceed 12 g/dL. For persons receiving
erythropoietin on a weekly dosing schedule, the dose should be increased to 60,000 units
weekly in adults (900 units/kg in children) if response is not satisfactory (i.e., if hemoglobin
fails to increase by 1 g/dL after 4 weeks of therapy) to achieve and maintain the lowest
hemoglobin level sufficient to avoid the need for transfusions not to exceed 12 g/dL.
According to the FDA-approved labeling of Procrit, the recommended range for the starting
dose of erythropoietin alpha for chronic renal failure is 50 to 100 units/kg 3 times weekly for
adult patients. The recommended starting dose for pediatric patients on dialysis is 50
units/kg 3 times a week. A Cochrane review by Cody et al (2005) found that there is no
significant difference between once-weekly versus thrice-weekly subcutaneous administration
of rHuEPO for patients with chronic renal failure on dialysis. According to the literature,
dosing should be discontinued if the hematocrit has not increased within 16 weeks, indicating
a non-responder. Accepted guidelines state that dosage should be decreased if the
hematocrit increases by more than 4 g/dL in any 2-week period. Dosing is adjusted after 8
weeks and at monthly intervals thereafter as necessary to maintain a hematocrit of 30 to 36
%. The FDA-approved labeling for Procrit states that the dose of erythropoietin should be
reduced as the hemoglobin approaches 11 g/dL or increases by more than 1 g/dL in any 2-
week period. The dose should be adjusted for each patient to achieve and maintain the
lowest hemoglobin level sufficient to avoid the need for RBC transfusion and not to exceed 11
g/dL. The labeling states that the dost of erythropoietin should be increased if the hemoglobin
does not increase by 2 g/dL after 8 weeks of therapy, and the hemoglobin remains at a level
not sufficient to avoid the need for a transfusion. The labeling states that the maintenance
Erythropoiesis Stimulating Agents Page 4 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
dose of erythropoietin should be individually titrated to achieve and maintain the lowest
hemoglobin sufficient to avoid the need for transfusions and not to exceed 11 g/dL.
The FDA-approved labeling for Procrit states that increases in dose should not be made more
frequently than once a month. If the hemoglobin is increasing and approaching 11 g/dL, the
dose should be reduced by approximately 25 %. If the hemoglobin continues to increase,
dose should be temporarily withheld until the hemoglobin begins to decrease, at which point
therapy should be reinitiated at a dose approximately 25 % below the previous dose. If the
hemoglobin increases by more than 1 g/dL in a 2-week period, the dose should be decreased
by approximately 25 %. The labeling states that, if the increase in hemoglobin is less than 1
g/dL over 4 weeks and iron stores are adequate, the dose of erythropoietin may be increased
by approximately 25 % of the previous dose. Further increases may be made at 4-week
intervals until the specified hemoglobin is obtained.
There is a lack of relliable evidence that one brand of erythropoietin alpha (Procrit or Epogen)
is more effective than another brand. In addition, there is a lack of reliable evidence that
darbepoetin (Aranesp) is more or less effective than erythropoietin alpha for
darbepoetin's established indications.
Recent data indicate that about half of patients undergoing dialysis in the United States have
their hemoglobin levels maintained at values above the maximum target (12 g/dL that was
specified in the product labeling for erythropoietin analogs at the time the study was
performed (Steinbrook, 2007). Some investigators have posited that maintaining higher
hemoglobin levels may benefit patients' quality of life. However, the Correction of
Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) study found that maintaining
higher hemoglobin levels increases patients' risk of serious and life-threatening
cardiovascular complications, including death (Singh et al, 2006). The CHOIR study found
that targeting a hemoglobin level of 13.5 g/dL (as compared with 11.3 g/dL) in patients with
chronic kidney disease who did not yet need dialysis was associated with a significantly
increased risk of a composite end point of death, myocardial infarction, hospitalization for
congestive heart failure (without renal-replacement therapy), and stroke. On November 16,
2006, the day the CHOIR study was published, the FDA issued a public health advisory to
"underscore the importance of following the currently approved prescribing information" by
raising hemoglobin levels no higher than 12 g/dL (FDA, 2006; Steinbrook, 2006).
More recently, the FDA (2011) announced that, for patients on dialysis, erythropoiesis-
stimulating agent (ESA) therapy can start when the hemoglobin level is less than 10 g/dL.
But, if the hemoglobin level approaches or goes over 11 g/dL, the dose of the drug should be
lowered or therapy stopped. FDA's announcement applies to patients with early-stage kidney
failure as well as those on dialysis, the treatment for late-stage kidney failure. The previous
labeling of ESAs recommended keeping patients' hemoglobin levels between 10 g/dL and 12
g/dL. The new label does away with that specific target range, stating only that physicians
should initiate ESAs if patients' hemoglobins fall below 10 g/dL." This labeling change was
prompted by studies that have found that hemoglobin levels greater than 11 g/dL of blood
increase the risk of stroke, heart attack, heart failure and thromboembolism and haven't been
proven to provide any additional benefit to patients. The revised labeling of ESAs states that
for patients with chronic kidney disease not on dialysis, ESA therapy can be started when the
hemoglobin level is less than 10 g/dL. However, the goal of treatment should not be to
increase hemoglobin levels to 10 or more g/dL. The FDA recommends that, if the hemoglobin
level exceeds 10 g/dL, the dose of ESA should be reduced or interrupted. For patients on
dialysis, ESA therapy can start when the hemoglobin level is less than 10 g/dL. But, if the
Erythropoiesis Stimulating Agents Page 5 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
hemoglobin level approaches or goes over 11 g/dL, the dose of the drug should be lowered or
therapy stopped, the FDA said.
The FDA was notified in February 2007 of the preliminary results of a 681-patient, multi-
center, randomized, open-label, non-inferiority study of erythropoietin alphoa compared with
the standard of care in adult patients undergoing elective spinal surgery. Erythropoietin
alpha was administered according to the dosage and administration section of the label for
pretreatment hemoglobin values greater than 10 and less than 13 g/dL. The frequency of
deep venous thrombosis in patients treated with erythropoietin alpha was 4.7 % (16 patients),
more than twice that of patients who received usual blood conservation care (frequency of 2.1
%, 7 patients).
The FDA-approved labeling for erythropoietin analogs has revised product labeling that
includes updated warnings, a new boxed warning, and modifications to the dosing instructions
(FDA, 2007). The new boxed warning advises physicians to monitor hemoglobin and to
adjust the erythropoietin analogs dose to maintain the lowest hemoglobin level needed to
avoid the need for blood transfusions. The labeling states that physicians and patients should
carefully weigh the risks of erythropoietin analogs against transfusion risks.
In 2007, the FDA ordered changes to the labeling of ESAs, restricting their use. The FDA
instructed manufacturers to change the labeling to reflect three major changes: the drugs are
"not indicated for those receiving myelosuppressive therapy when the anticipated outcome is
cure"; therapy should not be initiated at hemoglobin levels of 10 g/dL and above; and doses
should be withheld if hemoglobin levels exceed a level needed to avoid transfusion. The
black-box warnings for ESAs were updated with information on the increased risk for death
and tumor progression in patients with early breast cancer and cervical cancer. The warnings
note that ESAs pose higher risks when dosed to achieve hemoglobin levels of 12 g/dL or
higher, and risks at lower hemoglobin targets have not been excluded. Accordingly,
physicians are advised to use the lowest dose needed to avoid RBC transfusions. Previous
warnings have highlighted the risks for patients with non-small-cell lung, head and neck, and
lymphoid cancers.
Aranesp (darbepoetin alfa), also known as novel erythropoiesis stimulating protein (NESP), is
an erythropoiesis stimulating protein closely related to erythropoietin that is produced in
Chinese hamster ovary cells by recombinant DNA technology. This FDA- approved drug
stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. A primary
growth factor for erythroid development, erythropoietin is produced in the kidney and released
into the bloodstream in response to hypoxia. Erythropoietin interacts with progenitor stem
cells to increase red cell production. Production of endogenous erythropoietin is impaired in
patients with chronic renal failure, and erythropoietin deficiency is the primary cause of their
anemia. Aranesp is approved by the FDA for the treatment of anemia associated with chronic
renal failure, including patients on dialysis and patients not on dialysis. In addition, the U.S.
Pharmacopoeial Convention concluded that chemotherapy-induced anemia is an accepted
indication for darbepoetin alpha. Increased hemoglobin levels are not generally observed
until 2 to 6 weeks after initiating treatment with Aranesp. Aranesp has an approximately 3-
fold longer terminal half-life than Epoetin alfa when administered by either the IV or SC route
as a single weekly injection. The dose should be started and slowly adjusted based on
hemoglobin levels. The dose should be adjusted for each patient to achieve and maintain a
target hemoglobin level not to exceed 12 g/dL.
Erythropoiesis stimulating agents have not been proven to be effective for the treatment of
aplastic anemia. Erythropoietin levels are markedly elevated in most patients with aplastic
Erythropoiesis Stimulating Agents Page 6 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
anemia. Guidelines from the British Society of Haematology (2002) state that the routine use
of erythropoietin for aplastic anemia is "not recommended." The guidelines note the
limitations of evidence for erythropoietin in aplastic anemia. In addition, the guidelines note
that erythropoietin has the potential for inducing severe and sudden worsening of anemia due
to red cell aplasia from anti-erythropoietin antibodies. The guidelines also note that there is a
potential for toxicity when erythropoietin is used in combination with other drugs used
routinely to treat aplastic anemia, such as cyclosporin.
Several randomized controlled trials (RCTs) have examined the effectiveness of erythropoietin
in aplastic anemia. The most recent (Zeng et al, 2006) found that the addition of growth
factors (erythropoietin plus G-CSF) to immunosuppressive therapy did not improve outcomes
over immunosuppressive therapy alone. An earlier RCT by Bessho et al (1997) compared G-
CSF plus erythropoietin to erythropoietin alone, but did not include an appropriate comparison
to immunosuppressive therapy, which is the current standard of care for aplastic anemia.
Another earlier RCT by Shao et al (1998) compared immunosuppressive therapy to G-CSF
plus erythropoietin. Limitations of the study by Shao et al (1998) compared to the most recent
study by Zeng et al (2006) include its smaller size and its measurement of only intermediate
outcomes (response rates) rather than survival. Both studies are limited by the use of G-CSF
with erythropoietin, which does not allow us to isolate the effect of erythropoietin.
The lack of proven effectiveness of erythropoietin in aplastic anemia, coupled with the
potential noted by the British Society of Haematology for the sudden and severe worsening of
anemia due to red cell aplasia due to the induction of erythropoietin antibodies, plus the
synergistic toxic effects of erythropoietin when combined with cyclosporin and other drugs for
aplastic anemia, counsel against the use of erythropoietin as a treatment for aplastic anemia.
Several studies have documented an increased risk of venous thromboembolism (VTE) in
patients with cancer-associated anemia who are treated with the erythropoietin and
darbepoetin. In an updated investigation of safety concerns related to erythropoiesis
stimulating agents, Bennett and colleagues (2008) analyzed data from Phase III clinical trials
published or presented between January 1993 and January 2007 to assess ESA-associated
risks of VTE and mortality. The authors report that anemic patients with cancer who were
treated with ESAs had a 1.55-fold increased risk of VTE and a 1.10-fold increased risk of
mortality compared with patients who received placebo or standard care.
A number of clinical studies have examined the effect of erythropoietin analogs on cancer
progression, apart from its effect on chemotherapy-induced anemia. Clinical observations in
patients with multiple myeloma and animal studies have suggested that epoetin has an anti-
myeloma effect, mediated via the immune system through activation of CD8+ T cells. Thus,
the role of epoetin may go well beyond that of increasing hemoglobin levels in anemic
patients, although additional studies are needed to confirm these promising results.
There are other studies, however, which raise suspicion about negative effects of
erythropoietin on tumor size and survival in cancer patients (DACEHTA, 2004). In a multi-
center, RCT, Leyland-Jones et al (2005) assessed the effect on survival and quality of life of
maintaining hemoglobin (Hb) in the range of 12 to 14 g/dL with epoetin alfa versus placebo in
women with metastatic breast cancer (MBC) receiving first-line chemotherapy. Eligible
patients were randomly assigned to receive epoetin alfa 40,000 units once-weekly or placebo
for 12 months. Study drug was initiated if baseline Hb was less than or equal to 13 g/dL or
when Hb decreased to less than or equal to 13g/dL during the study. The primary end point
was 12-month overall survival (OS). The study drug administration was stopped early in
Erythropoiesis Stimulating Agents Page 7 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
accordance with a recommendation from the Independent Data Monitoring Committee
because of higher mortality in the group treated with epoetin alfa. Enrollment had been
completed, with 939 patients enrolled (epoetin alfa, n = 469; placebo, n = 470). Most patients
had Hb more than 12 g/dL at baseline (median Hb, 12.8 g/dL) or during the study. From the
final analysis, 12-month OS was 70 % for epoetin alfa recipients and 76 % for placebo
recipients (p = 0.01). Optimal tumor response and time to disease progression were similar
between groups. The reason for the difference in mortality between groups could not be
determined from additional subsequent analyses involving both study data and chart review.
These researchers concluded that the use of epoetin alfa to maintain high Hb targets in
women with MBC, most of whom did not have anemia at the start of treatment, was
associated with decreased survival. Additional research is needed to clarify the potential
impact of erythropoietic agents on survival when the Hb target range is 10 to 12 g/dL.
In a multicenter, randomized, double-blind, placebo-controlled trial, Wright et al (2007) found
decreased OS in anemic patients with advanced non-small-cell carcinoma of the lung
(NSCLC) treated with epoetin alpha. In this clinical study, the proposed sample size was 300
patients. Eligible patients were required to have NSCLC unsuitable for curative therapy and
baseline hemoglobin (Hgb) levels less than 12 g/dL. Patients were assigned to 12 weekly
injections of subcutaneous epoetin alpha or placebo, targeting Hgb levels between 12 and 14
g/dL. The study was intended to evaluate the effect of epoietin administration on quality of
life. However, reports of thrombotic events in other trials of erythropoietin analogs prompted
an unplanned safety analysis after 70 patients had been randomly assigned (33 to the active
arm and 37 to the placebo arm). This revealed a significant difference in the median survival
in favor of the patients on the placebo arm of the trial (63 verus 129 days; hazard ratio, 1.84;
p = 0.04). Because of the poorer outcomes in the erythropoietin-treated patients, the Steering
Committee closed the trial. The authors concluded that this unplanned safety analysis
suggested decreased OS in patients with advanced NSCLC treated with epoetin alfa.
Randomized controlled clinical studies of the use of erythropoietin analogs in other types of
cancer (head and neck cancer, lung cancer, lymphoproliferative disorders) have similarly
found no improvements in progression-free survival or OS (Hedenus et al, 2005).
Interim results from the Danish Head and Neck Cancer Study Group trial (DAHANCA 10), an
open-label, randomized trial that compared radiation therapy alone to radiation plus
darbepoietin in treatment of advanced head and neck cancer found that 3-year loco-regional
control was significantly worse for patients in the darbepoetin arm (p = 0.01) and OS favored
those not treated with Aranesp, but the difference was not statistically significant (FDA,
2007). The trial was terminated December 2006. Results similar to the DAHANCA 10 study -
- increased tumor progression and decreased survival -- were reported by Henke et al at the
May 4, 2004, meeting of the FDA's Oncologic Drugs Advisory Committee.
In January 2007 the FDA was notified of the results of a 989-patient, multi-center, double-
blind, randomized, placebo-controlled study of darbepoetin in anemic cancer patients who are
not receiving chemotherapy (FDA, 2007). The target hemoglobin in the darbepoetin
treatment group was 12 g/dL. The study results provided to the FDA show darbepoetin did
not reduce the need for RBC transfusions and showed an increase in mortality in patients
receiving Aranesp compared to those receiving placebo (hazard ratio 1.25; 95 % confidence
interval [CI]: 1.04 to 1.51).
The FDA was notified in February 2007 of the final results of a double-blind, placebo controlled
study to evaluate whether use of epoetin alpha in anemic NSCLC patients not on
chemotherapy improved their quality of life (FDA, 2007). The epoetin alfa dose was titrated to
Erythropoiesis Stimulating Agents Page 8 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
maintain a hemoglobin level of 12 to 14 g/dL; epoetin alfa was dosed at 40,000 IU every
week. The study was terminated early when the data safety monitoring committee
determined that the median time to death was 68 days in the epoetin alfa arm versus 131
days in the placebo arm (p = 0.040) and the majority of deaths were due to disease
progression. Also treatment with epoetin alfa did not significantly reduce the need for
transfusion or improve the quality of life.
In February 2007, the FDA was notified by Roche that it was suspending a study of a new
ESA because of safety concerns (FDA, 2007). The study was a multi-center, randomized,
dose-finding assessment of a pegylated epoetin beta product in anemic patients with Stage
IIIB or IV NSCLC who were receiving first line chemotherapy. Three dosing regimens of the
investigational drug were being compared with Aranesp (given according to an FDA-approved
dosing regimen). The dose of pegylated epoetin beta was titrated to maintain the hemoglobin
level between 11 and 13 g/dL. An interim analysis, after randomization of 153 patients,
demonstrated a numerical imbalance in the number of deaths across the 4 arms of the study.
Based on the results of a recent clinical trial of darbepoetin in cancer-related anemia, National
Comprehensive Cancer Network (NCCN) updated its guidelines to recommend against the
administration of erythropoetin to patients with cancer related anemia similar to the
darbepoetin trial conducted by Amgen (NCCN, 2007). The NCCN panel added a statement
to the “Adverse Effects of Erythropoietic Therapy” section of the guidelines, stating that, until
new research evidence changes current benefit/risk estimates, physicians should be advised
not to administer erythropoietin to patients similar to those in the Amgen trial.
Regarding use of erythropoietin analogs as a treatment for cancer, a technology assessment
by the Danish Centre for Evaluation and Health Technology Assessment (DACEHTA, 2004)
concluded: “At present there is not sufficient evidence that EPO [erythropoietin] treatment has
an effect on the cancer disease itself. Therefore, EPO treatment should not be regarded as a
treatment of cancer as such, but rather as a treatment of the side effects of the
chemotherapy.”
An assessment by the National Institute for Health and Clinical Excellence (NICE, 2008) of
erythropoietin analog therapy for cancer chemotherapy induced anemia recommended that
erythropoietin only be used as part of clinical trials that are constructed to generate robust
and relevant data in order to address the gaps in the currently available evidence. The
assessment reported that some studies had shown benefits with erythropoietin in terms of
improved survival, but that the results of other studies were consistent with a detrimental
effect. The assessment also noted that there are biologically plausible reasons to suggest
possible growth-enhancing effects of erythropoietin on some tumors. The assessment
therefore concluded that the true effect of erythropoietin on survival remains unknown. The
assessment noted that clinical trials examining the effects of erythropoietin on various
measures of health-related quality of life had significant methodological weaknesses.
Although most studies suggested that erythropoietin improved health-related quality of life,
the additional benefits over standard care (i.e., blood transfusions and iron therapy where
indicated) were small. The assessment found that the benefits of erythropoietin in reducing
the need for blood transfusions were modest: in trials comparing erythropoietin therapy to
standard care involving blood transfusions, erythropoietin therapy reduced the requirement for
blood transfusions by approximately 1 unit per patient overall. The assessment also reported
that fatigue in patients with cancer has a number of potential contributory factors, and that it is
difficult in individual cases to determine the exact contribution of anemia to this symptom.
Erythropoiesis Stimulating Agents Page 9 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
Emerging safety concerns (thrombosis, cardiovascular events, tumor progression, and
reduced survival) derived from clinical trials in several cancer and non-cancer populations
prompted the CMS to review its coverage of erythropoietin analog therapy. CMS (2007)
determined that erythropoietin analog therapy is not reasonable and necessary for the
following clinical conditions, either because of a deleterious effect of erythropoietin analogs on
the underlying disease or because the underlying disease increases their risk of adverse
effects related to erythropoietin analog use. These conditions include:
Anemia due to cancer treatment if patients have uncontrolled hypertension;
Any anemia associated only with radiotherapy;
Any anemia in cancer or cancer treatment patients due to folate deficiency, B-12
deficiency, iron deficiency, hemolysis, bleeding, or bone marrow fibrosis;
Patients with erythropoietin-type resistance due to neutralizing antibodies;
Prophylactic use to prevent chemotherapy-induced anemia;
Prophylactic use to reduce tumor hypoxia;
The anemia associated with the treatment of acute and chronic myelogenous
leukemias (CML, AML), or erythroid cancers; and
The anemia of cancer not related to cancer treatment;
In a phase III, multi-center, randomized, double-blind, placebo-controlled study, Smith and
colleagues (2008) examined the effects of darbepoetin alpha (DA) for the treatment of anemia
in patients with active cancer not receiving or planning to receive chemotherapy or
radiotherapy. Patients were administered placebo or DA 6.75 microg/kg every 4 weeks
(Q4W) for up to 16 weeks with a 2-year follow-up for survival. Patients who completed 16
weeks of treatment could receive the same treatment as randomized Q4W for an additional
16 weeks. The primary end point was all occurrences of transfusions from weeks 5 through
17; safety end points included incidence of adverse events and survival. The incidence of
transfusions between weeks 5 and 17 was lower in the DA group but was not statistically
significantly different from that of placebo. Darbepoetin alpha was associated with an
increased incidence of cardiovascular and thromboembolic events and more deaths during
the initial 16-week treatment period. Long-term survival data demonstrated statistically
significantly poorer survival in patients treated with DA versus placebo (p = 0.022). This
effect varied by baseline co-variates including, sex, tumor type, and geographic region;
statistical significance diminished (p = 0.12) when the analysis was adjusted for baseline
imbalances or known prognostic factors. The authors concluded that DA was not associated
with a statistically significant reduction in transfusions. Shorter survival was observed in the
DA arm; thus, this study does not support the use of ESA in this subset of patients with
anemia of cancer.
The Centers for Medicare and Medicaid Services (CMS, 2007) has developed evidence
based guidelines for dosing of erythropoietin analog therapy in persons with end-stage renal
disease. CMS issued a final policy, effective April 2006, that, for claims for erythropoietin
analog therapy in persons with hematocrit readings above a threshold of 39.0 % (or
hemoglobin above 13.0 g/dL), the dose should be reduced by 25 % over the preceding
month. Since that time, there have been several publications and an FDA “black box”
warning that emphasize the risks facing end-stage renal disease patients who receive large
doses of erythropoietin analogues and have higher hematocrits. In response to those
concerns, CMS modified its erythropoietin analog therapy monitoring policy to provide greater
restrictions on the amount of erythropoietin analogs for which payment is made at higher
levels of hemoglobin. Effective for dates of service on or after January 1, 2008, for requests
Erythropoiesis Stimulating Agents Page 10 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
for payments or claims for erythropoietin analog therapy for end-stage renal disease patients
receiving dialysis in renal dialysis facilities and reporting a hematocrit level exceeding 39.0 %
(or hemoglobin exceeding 13.0 g/dL) for 3 or more consecutive billing cycles immediately
prior to and including the current billing cycle, the erythropoietin analog dose for which
payment may be made shall be reduced by 50 % of the reported dose.
The discovery that erythropoietin and its receptor are located in regions outside the
erythropoietic system has led to interest in the potential role of epoetin in other tissues, such
as the central nervous system (Boogaerts et al, 2005). Bath and Sprigg (2005) report that
erythropoietin was neuroprotective in experimental stroke and increased functional recovery,
effects possibly mediated by inhibiting apoptosis in the penumbra. They note that, in a small
clinical trial, erythropoietin was well-tolerated in stroke patients. Erythropoietin for stroke is
currently being assessed in Phase II clinical trials. Bath and Sprigg (2005) reported that
derivatives of erythropoietin which do not alter red cell kinetics but retain their neuroprotective
activity have been developed, but clinical studies of these have yet to be reported.
However, more recent evidence suggests that erythropoiesis stimulating agents may increase
stroke risk. The FDA (2008) stated that erythropoietin may carry heightened mortality risk
when used to improve functional outcomes in stroke patients. In a clinical trial conducted in
Germany, patients with acute ischemic stroke who received intravenous Eprex brand of
erythropoietin (40,000 units daily for 3 days) were more likely to die within 90 days than were
those on placebo (16 % versus 9 %). In particular, death from intracranial hemorrhage
occurred in 4 % of Eprex recipients and 1 % of placebo recipients. The FDA noted, however,
that the dose used was "considerably higher" than the erythropoietin doses approved for the
treatment of anemia.
Erythropoesis stimulating agents have not been proven to improve outcomes in persons with
heart failure and anemia. In the randomized, double-blind, placebo-controlled Study of
Anemia and Heart Failure Trial (STAMINA-HeFT), investigators evaluated the effects of
treating anemia in patients with heart failure (Ghali et al, 2008). A total of 319 patients with
symptomatic heart failure were randomized to placebo or darbepoetin for 52 weeks. The
median hemoglobin level in the darbepoetin group increased by 1.5 g/dL from baseline to 12
to 14 weeks of treatment; target hemoglobin concentrations were maintained in the
darbepoetin group for the remainder of the study period. At week 27, however, the groups did
not differ significantly in mean change from baseline in either exercise duration or New York
Heart Association functional class.
The American College of Obstetricians and Gynecologists' (ACOG, 2008) practice bulletin on
anemia in pregnancy makes no recommendation for use of erythropoietin in pregnancy
(2008). The bulletin states: "Few studies have examined the role of erythropoietin in pregnant
patients with anemia." The ACOG practice bulletin cited two randomized controlled clinical
studies of erythropoietin plus iron versus iron alone in anemia of pregnancy and postpartum
anemia, with contrasting results (citing Breymann et al, 2001; Wagstrom et al, 2007).
Pfeffer and colleagues (2009) stated that anemia is associated with an increased risk of
cardiovascular and renal events among patients with type 2 diabetes and chronic kidney
disease (CKD). Although darbepoetin alfa can effectively increase Hb levels, its effect on
clinical outcomes in these patients has not been adequately tested. In this study involving
4,038 patients with diabetes, CKD, and anemia, these investigators randomly assigned 2,012
patients to darbepoetin alfa to achieve a Hb level of about 13 g/dL and 2,026 patients to
placebo, with rescue darbepoetin alfa when the Hb level was less than 9.0 g/dL. The primary
end points were the composite outcomes of death or a cardiovascular event (non-fatal
Erythropoiesis Stimulating Agents Page 11 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
myocardial infarction, congestive heart failure, stroke, or hospitalization for myocardial
ischemia) and of death or end-stage renal disease. Death or a cardiovascular event occurred
in 632 patients assigned to darbepoetin alfa and 602 patients assigned to placebo (hazard
ratio for darbepoetin alfa versus placebo, 1.05; 95 % CI: 0.94 to 1.17; p = 0.41). Death or end
-stage renal disease occurred in 652 patients assigned to darbepoetin alfa and 618 patients
assigned to placebo (hazard ratio, 1.06; 95 % CI: 0.95 to 1.19; p = 0.29). Fatal or non-fatal
stroke occurred in 101 patients assigned to darbepoetin alfa and 53 patients assigned to
placebo (hazard ratio, 1.92; 95 % CI: 1.38 to 2.68; p < 0.001). Red-cell transfusions were
administered to 297 patients assigned to darbepoetin alfa and 496 patients assigned to
placebo (p < 0.001). There was only a modest improvement in patient-reported fatigue in the
darbepoetin alfa group as compared with the placebo group. The authors concluded that the
use of darbepoetin alfa in patients with diabetes, CKD, and moderate anemia who were not
undergoing dialysis did not reduce the risk of either of the 2 primary composite outcomes
(either death or a cardiovascular event or death or a renal event) and was associated with an
increased risk of stroke. For many persons involved in clinical decision making, this risk will
out-weigh the potential benefits.
The findings by Pfeffer et al (2009) are in agreement with those of the CHOIR study (Singh et
al, 2006) as well as the CREATE study (Drüeke et al, 2006). Singh and colleagues reported
that targeting a Hb level of 13.5 g/dL (as compared with 11.3 g/dL) in patients with CKD who
did not yet need dialysis was associated with a significantly increased risk of a composite end
point of death, myocardial infarction, hospitalization for congestive heart failure (without renal-
replacement therapy), and stroke. Furthermore, Drüeke and associates found that in patients
with stage 3 or stage 4 CKD, early complete correction of anemia (Hb levels of 13.0 to 15.0
g/dL) does not reduce the risk of cardiovascular events.
Ehrenreich et al (2009) stated that many pre-clinical findings and a clinical pilot study
suggested that recombinant human EPO provides neuroprotection that may be beneficial for
the treatment of patients with ischemic stroke. Although EPO has been considered to be a
safe and well-tolerated drug over 20 years, recent studies have identified increased
thromboembolic complications and/or mortality risks on EPO administration to patients with
cancer or CKD. Accordingly, the double-blind, placebo-controlled, randomized German
Multicenter EPO Stroke Trial was designed to evaluate safety and effectiveness of EPO in
stroke. This clinical trial enrolled 522 patients with acute ischemic stroke in the middle
cerebral artery territory (intent-to-treat population) with 460 patients treated as planned (per-
protocol population). Within 6 hours of symptom onset, at 24 and 48 hours, EPO was infused
intravenously (40,000 IU each). Systemic thrombolysis with recombinant tissue plasminogen
activator was allowed and stratified for. Unexpectedly, a very high number of patients
received recombinant tissue plasminogen activator (63.4 %). On analysis of total intent-to-
treat and per-protocol populations, neither primary outcome Barthel Index on Day 90 (p =
0.45) nor any of the other outcome parameters showed favorable effects of EPO. There was
an overall death rate of 16.4 % (n = 42 of 256) in the EPO and 9.0 % (n = 24 of 266) in the
placebo group (OR, 1.98; 95 % CI: 1.16 to 3.38; p = 0.01) without any particular mechanism
of death unexpected after stroke. The authors concluded that based on analysis of total
intent-to-treat and per-protocol populations only, this is a negative trial that also raises safety
concerns, particularly in patients receiving systemic thrombolysis.
In a matched case control study, Talving and co-workers (2010) examined if administration of
ESA would improve survival following severe traumatic brain injury (sTBI). Patients with sTBI
[head Abbreviated Injury Scale (AIS), greater than or equal to 3] receiving ESA while in the
surgical intensive care unit (n = 89) were matched 1 to 2 (n = 178) by age, gender,
Erythropoiesis Stimulating Agents Page 12 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
mechanism of injury, Glasgow Coma Scale, presence of hypotension on admission, Injury
Severity Score, AIS for all body regions, and presence of anemia with patients who did not
receive the agent. Each case's controls were chosen to have surgical intensive care unit
length of stay more than or equal to the time from admission to first dose of ESA. The
primary outcome measure in this study was mortality. Cases and controls had similar age,
gender, mechanisms of injury, incidence of hypotension, Glasgow Coma Scale on admission,
Injury Severity Score, and AIS for all body regions. Although the ESA-treated patients
experienced protracted hospital length of stay and comparable surgical intensive care unit
free days, they demonstrated a significantly lower in-hospital mortality in comparison to
controls at 7.9 % versus 24.2 %, respectively (OR: 0.27; 95 % CI: 0.12 to 0.62; p = 0.001).
The authors concluded that administration of ESA in sTBI is associated with a significant in-
hospital survival advantage without increase in morbidity. They stated that prospective, large,
randomized controlled trials are needed to validate these findings.
In an editorial that accompanied the afore-mentioned study, Velmahos (2010) stated that the
results serve more to provoke questions than provide answers. One of the questions is that
"ESA was administered subcutaneously, a method with notorious unreliable absorption
among critically ill patients. How do the authors assure us about adequate levels of the drug?
If drug levels are inadequate in the blood stream and organ tissues, how can we accept
causation between ESA and the purported outcome improvement?". Velmahos also noted
that "[n]o information is provided about the timing of ESA administration, except that it was
administered "within the first 2 weeks". However, according to Figure 2 most deaths also
occurred within the first 2 weeks in the no-ESA group. This means that ESA saved patients
from relatively early deaths. One should assume that a single injection prevented a patient
from dying the next day. What exactly is this powerful quality of ESA that can reverse death
so drastically? If the effects act through an amelioration of a rampant post-traumatic cascade,
how is it that ESA patients suffered more complications?"
Ehrenreich and colleagues (2007) stated that the neurodegenerative aspects of chronic
progressive multiple sclerosis (MS) have received increasing attention in recent years, since
anti-inflammatory and immunosuppressive treatment strategies have largely failed. However,
successful neuroprotection and/or neuroregeneration in MS have not been demonstrated yet.
Encouraged by the multi-faceted neuroprotective effects of rHuEPO in experimental
models, these researchers performed an investigator-driven, pilot open-label study (phase
I/IIa) in patients with chronic progressive MS. Main study objectives were (i) evaluating safety
of long-term high-dose intravenous rHuEPO treatment in MS, and (ii) collecting first evidence
of potential efficacy on clinical outcome parameters. A total of 8 MS patients -- 5 randomly
assigned to high-dose (48,000 IU), 3 to low-dose (8000 IU) rHuEPO treatment; and, as
disease controls, 2 drug-naïve Parkinson patients (receiving 48,000 IU) were followed over up
to 48 weeks: A 6-week lead-in phase, a 12-week treatment phase with weekly EPO, another
12-week treatment phase with bi-weekly EPO, and a 24-week post-treatment phase. Clinical
and electrophysiological improvement of motor function, reflected by a reduction in expanded
disability status scale (EDSS), and of cognitive performance was found upon high-dose EPO
treatment in MS patients, persisting for 3 to 6 months after cessation of EPO application. In
contrast, low-dose EPO MS patients and drug-naïve Parkinson patients did not improve in
any of the parameters tested. There were no adverse events, no safety concerns and a
surprisingly low need of blood-lettings. The authors concluded that the findings of this pilot
study demonstrated the necessity and feasibility of RCTs using high-dose rHuEPO in chronic
progressive MS.
Erythropoiesis Stimulating Agents Page 13 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
Endre and colleagues (2010) performed a double-blind, placebo-controlled trial to study
whether early treatment with erythropoietin could prevent the development of acute kidney
injury in patients in 2 general intensive care units. As a guide for choosing the patients for
treatment, these researchers measured urinary levels of 2 biomarkers: (i) the proximal tubular
brush border enzymes gamma-glutamyl transpeptidase, and (ii) alkaline phosphatase.
Randomization to either placebo or 2 doses of erythropoietin was triggered by an increase in
the biomarker concentration product to levels above 46.3, with a primary outcome of relative
average plasma creatinine increase from baseline over 4 to 7 days. Of 529 patients, 162
were randomized within an average of 3.5 h of a positive sample. There was no difference in
the incidence of erythropoietin-specific adverse events or in the primary outcome between the
placebo and treatment groups. The triggering biomarker concentration product selected
patients with more severe illness and at greater risk of acute kidney injury, dialysis, or death;
however, the marker elevations were transient. Early intervention with high-dose
erythropoietin was safe but did not alter the outcome. Although these 2 urine biomarkers
facilitated early intervention, their transient increase compromised effective triaging.
Furthermore, this study showed that a composite of these 2 biomarkers was insufficient for
risk stratification in a patient population with a heterogeneous onset of injury.
In a review on the potential of cytokines and growth factors in the treatment of ischemic heart
disease, Beohar et al (2010) stated that cytokine therapy promises to provide a non-invasive
treatment option for ischemic heart disease. Several cytokines mobilize progenitor cells from
the bone marrow or are involved in the homing of mobilized cells to ischemic tissue. The
recruited cells contribute to myocardial regeneration both as a structural component of the
regenerating tissue and by secreting angiogenic or anti-apoptotic factors, including cytokines.
To date, RCTs have not reproduced the efficacy observed in pre-clinical and small-scale
clinical investigations. Nevertheless, the list of promising cytokines continues to grow, and
combinations of cytokines, with or without concurrent progenitor cell therapy, warrant further
investigation. In particular, the authors noted that a long-acting EPO analog, darbepoetin
alpha, was safely administered to patients with acute myocardial infarction (MI), but provided
no functional benefit. The administration of EPO to patients with acute MI continues to be
investigated in the ongoing HEBE III and REVEAL clinical trials.
The American Society of Clinical Oncology/American Society of Hematology clinical practice
guideline update on the use of epoetin and darbepoetin in adult patients with cancer (Rizzo et
al, 2010) stated that for patients undergoing myelosuppressive chemotherapy who have
a Hgb level less than 10 g/dL, the Update Committee recommends that clinicians discuss
potential harms (e.g., thromboembolism, shorter survival) and benefits (e.g., decreased
transfusions) of ESAs and compare these with potential harms (e.g., serious infections,
immune-mediated adverse reactions) and benefits (e.g., rapid Hgb improvement) of RBC
transfusions. Individual preferences for assumed risk should contribute to shared decisions on
managing chemotherapy-induced anemia. The Committee cautions against ESA use under
other circumstances. If used, ESAs should be administered at the lowest dose possible and
should increase Hgb to the lowest concentration possible to avoid transfusions. Available
evidence does not identify Hgb levels greaterthan or equal to 10 g/dL either as thresholds for
initiating treatment or as targets for ESA therapy. Starting doses and dose modifications after
response or non-response should follow FDA-approved labeling. Erythropoiesis-stimulating
agents should be discontinued after 6 to 8 weeks in non-responders; they should be avoided
in patients with cancer not receiving concurrent chemotherapy, except for those with lower
risk myelodysplastic syndromes. Caution should be exercised when using ESAs with
Erythropoiesis Stimulating Agents Page 14 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
chemotherapeutic agents in diseases associated with increased risk of thromboembolic
complications.
Endre et al (2010) performed a double-blind placebo-controlled trial to study whether early
treatment with EPO could prevent the development of AKI in patients in 2 general intensive
care units. As a guide for choosing the patients for treatment, these researchers measured
urinary levels of 2 biomarkers, the proximal tubular brush border enzymes gamma-glutamyl
transpeptidase and alkaline phosphatase. Randomization to either placebo or 2 doses of
erythropoietin was triggered by an increase in the biomarker concentration product to levels
above 46.3, with a primary outcome of relative average plasma creatinine increase from
baseline over 4 to 7 days. Of 529 patients, 162 were randomized within an average of 3.5 hrs
of a positive sample. There was no difference in the incidence of EPO-specific adverse
events or in the primary outcome between the placebo and treatment groups. The triggering
biomarker concentration product selected patients with more severe illness and at greater risk
of AKI, dialysis, or death; however, the marker elevations were transient. Early intervention
with high-dose EPO was safe but did not alter the outcome. Although these 2 urine
biomarkers facilitated early intervention, their transient increase compromised effective
triaging. Further, this study showed that a composite of these 2 biomarkers was insufficient
for risk stratification in a patient population with a heterogeneous onset of injury.
In a systematic review of randomized trials on erythropoietin as a treatment of anemia in heart
failure, Kotecha et al (2011) reviewed the effects of ESAs in chronic heart failure. An
extensive search strategy identified 11 RCTs with 794 participants comparing any ESA with
control over 2 to 12 months of follow-up. Published and additionally requested data were
incorporated into a Cochrane systematic review (CD007613). A total of 9 studies were
placebo controlled, and 5 were double blinded. Erythropoiesis-stimulating agent treatment
significantly improved exercise duration by 96.8 seconds (95 % CI: 5.2 to 188.4, p = 0.04) and
6-min walk distance by 69.3 m (95 % CI: 17.0 to 121.7, p = 0.009) compared with control.
Benefit was also noted for peak oxygen consumption (+2.29 ml/kg/min, p = 0.007), New York
Heart Association class (-0.73, p < 0.001), ejection fraction (+5.8 %, p < 0.001), B-type
natriuretic peptide (-226.99 pg/ml, p < 0.001), and quality-of-life indicators with a mean
increase in hemoglobin level of 2 g/dL. There was a significantly lower rate of heart failure-
related hospitalizations with ESA therapy (odds ratio 0.56, 95 % CI: 0.37 to 0.84, p = 0.005).
No associated increase in adverse events or mortality (odds ratio 0.58, 95 % CI: 0.34 to 0.99,
p = 0.047) was observed, although the number of events was limited. The authors concluded
that meta-analysis of small RCTs suggested that ESA treatment can improve exercise
tolerance, reduce symptoms, and have benefits on clinical outcomes in anemic patients with
heart failure. Moreover, they stated that confirmation requires larger, well-designed studies
with careful attention to dose, attained Hb level, and long-term outcomes. This is in
agreement with the observations of Lipsic et al (2011) as well as Santilli et al (2011). Lipsic
and colleagues (2011) stated that large-scale trials with ESAs are needed to examine the
safety and effectiveness of anemia treatment in patients with heart failure. Santilli and
associates (2011) stated that further studies are needed to define the magnitude of the
problem and establish appropriate therapeutic strategies. It is likely that more reliable data
will be derived from an ongoing randomized, double-blind, multi-center study, the RED-HF
(Reduction Event with Darbepoetin alfa in Heart Failure), which aims at evaluating morbidity
and mortality in a cohort of 2,600 heart failure patients with anemia treated with darbepoetin
alfa.
In a prospective, randomized, double-blind, placebo-controlled trial with a dose-escalation
safety phase and a single dose (60,000 U of epoetin alfa) efficacy phase, Najjar et al (2011)
Erythropoiesis Stimulating Agents Page 15 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
evaluated the safety and effectiveness of a single intravenous bolus of epoetin alfa in patients
with acute ST-segment elevation myocardial infarction (STEMI). The Reduction of Infarct
Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction
(REVEAL) trial was conducted at 28 U.S. sites between October 2006 and February 2010,
and included 222 patients with STEMI who underwent successful percutaneous coronary
intervention (PCI) as a primary or rescue reperfusion strategy. Participants were randomly
assigned to treatment with intravenous epoetin alfa or matching saline placebo administered
within 4 hours of re-perfusion. Main outcome measure was infarct size, expressed as
percentage of left ventricle (LV) mass, assessed by cardiac magnetic resonance (CMR)
imaging performed 2 to 6 days after study medication administration (first CMR) and again 12
+/- 2 weeks later (second CMR). In the efficacy cohort, the infarct size did not differ between
groups on either the first CMR scan (n = 136; 15.8 % LV mass [95 % CI: 13.3 to 18.2 % LV
mass] for the epoetin alfa group versus 15.0 % LV mass [95 % CI: 12.6 to 17.3 % LV mass]
for the placebo group; p = 0.67) or on the second CMR scan (n = 124; 10.6 % LV mass [95 %
CI: 8.4 to 12.8 % LV mass] versus 10.4 % LV mass [95 % CI: 8.5 to 12.3 % LV mass],
respectively; p = 0.89). In a pre-specified analysis of patients aged 70 years or older (n = 21),
the mean infarct size within the first week (first CMR) was larger in the epoetin alfa group
(19.9 % LV mass; 95 % CI: 14.0 to 25.7 % LV mass) than in the placebo group (11.7 % LV
mass; 95 % CI: 7.2 to 16.1 % LV mass) (p = 0.03). In the safety cohort, of the 125 patients
who received epoetin alfa, the composite outcome of death, MI, stroke, or stent thrombosis
occurred in 5 (4.0 %; 95 % CI: 1.31 % to 9.09 %) but in none of the 97 who received placebo
(p = 0.04). The authors concluded that in patients with STEMI who had successful re-
perfusion with primary or rescue PCI, a single intravenous bolus of epoetin alfa within 4 hours
of PCI did not reduce infarct size and was associated with higher rates of adverse
cardiovascular events. Subgroup analyses raised concerns about an increase in infarct size
among older patients.
In an editorial that accompanied the afore-mentioned study, Bhatt (20110 stated that "[b]
ecause these findings appeared in a blinded trial, they raise further questions about the safety
of epoetin alfa in the context of acute MI .... Until compelling data become available to support
routine sue of these agents in patients with anemia, it would be prudent to minimize their use,
especially in patients at high risk for cardiovascular disease or with an acute ischemic
syndrome".
Peginesatide is a new synthetic, pegylated, peptide-based ESA that aids in the formation of
RBCs. It works by stimulating the bone marrow to produce more RBCs to reduce the need
for transfusions in patients with CKD. Doss and Schiller (2010) statedthat peginesatide is a
peptide-based ESA for increasing and maintaining Hb. In phase 2 studies, peginesatide
increases and maintains target Hb levels in patients with CKD, both those on hemodialysis
and those not on hemodialysis; phase 3 trials have recently been completed. The
authors discussed unmet needs in the management of anemia of CKD, presented
peginesatide attributes, reviewed the results of select peginesatide clinical studies, and
discussed the potential value of peginesatide as an alternative anemia management option.
Macdougall et al (2011) examined the safety and effectiveness of peginesatide in correcting
renal anemia in a population of 139 non-dialysis CKD patients. Chronic kidney disease
patients who were not on dialysis and not receiving treatment with ESAs in the 12 weeks
before study drug administration were sequentially assigned to 1 of 10 cohorts; cohorts
differed in starting peginesatide dose (different body weight-based or absolute doses), route
of administration (intravenous or subcutaneous), and frequency of administration (every 2 or 4
weeks). Across all cohorts, 96 % of patients achieved a Hb response. A dose-response
Erythropoiesis Stimulating Agents Page 16 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
relationship was evident for Hb increase. Comparable subcutaneous and intravenous
peginesatide doses produced similar Hb responses. Rapid rates of Hb rise and Hb
excursions greater than 13 g/dL tended to occur more frequently with every 2-weeks dosing
than they did with every 4-weeks dosing. The range of final median doses in the every 4-
weeks dosing groups was 0.019 to 0.043 mg/kg. Across all cohorts, 20 % of patients
reported serious adverse events (1 patient had a possibly drug-related serious event) and 81
% reported adverse events (11.5 % reported possibly drug-related events); these events were
consistent with those routinely observed in this patient population. The authors concluded
that the findings of this study suggested that peginesatide administered every 4 weeks can
increase and maintain Hb in non-dialysis CKD patients. They stated that additional long-term
data in larger groups of patients are required to further elucidate the safety and efectiveness
of this peptide-based ESA.
On March 27, 2012, the FDA approved peginesatide (Omontys) to treat anemia in adult
dialysis patients who have CKD. Omontys represents the first new FDA-approved and
marketed ESA for this condition since 2001. The approval of Omontys was based on 2
randomized, active-controlled, open-label, multi-center clinical trials, which showed the safety
and effectiveness of Omontys in patients with CKD who were on dialysis. The trials randomly
selected a total of 1,608 patients with Hb levels initially stabilized by ESA to receive either
Omontys once-monthly or to continue their current ESA (epoetin) treatment. Results showed
that Omontys was as safe and effective as epoetin in maintaining Hb levels within the studies’
pre-specified range of 10 to 12 g/dL. The most common side effects observed in 10 % or
more of dialysis patients treated with Omontys were arthralgia, diarrhea, hypertension and
vomiting.
According to the FDA-approved labeling, Omontys should not be used in patients with CKD
who are not receiving dialysis or in patients with cancer-related anemia. Furthermore, it
should not be used as a substitute for RBC transfusions in patients who require immediate
correction of anemia. Omontys is administered as a once-monthly injection.
On February 24, 2013, the FDA alerted health care providers and patients of a voluntary
nationwide recall of all lots of Omontys injection by Affymax, Inc. (Palo Alto, CA) and Takeda
Pharmaceuticals Company Limited (Deerfield, IL). The recall is due to reports of
anaphylaxis. The FDA stated that until further notice, health care providers should stop using
Omontys and return the product to Takeda Pharmaceuticals. According to the companies,
serious and fatal hypersensitivity reactions have been reported in some patients receiving
their first dose of Omontys, given by intravenous injection. The reactions have occurred
within 30 minutes following the dose. There have been no reports of reactions following
subsequent dosing, or in patients who have completed their dialysis session. The FDA was
notified by Affymax of 19 reports of anaphylaxis from dialysis centers in the United States; 3
of the anaphylaxis cases resulted in death. Other patients required prompt medical
intervention and in some cases hospitalization. Some of the reports included patients who
were able to be resuscitated by doctors.
MacDougall et al (2013) evaluated the safety and efficacy of peginesatide, as compared with
darbepoetin, in 983 such patients who were not undergoing dialysis. In 2 randomized,
controlled, open-label studies (PEARL 1 and 2), patients received peginesatide once a month,
at a starting dose of 0.025 mg or 0.04 mg/kg of body weight, or darbepoetin once every 2
weeks, at a starting dose of 0.75 μg/kg. Doses of both drugs were adjusted to achieve and
maintain Hb levels between 11.0 and 12.0 g per deciliter for 52 weeks or more. The primary
efficacy end point was the mean change from the baseline Hb level to the mean level during
Erythropoiesis Stimulating Agents Page 17 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
the evaluation period; non-inferiority was established if the lower limit of the 2-sided 97.5 % CI
was -1.0 g/dL or higher. Cardiovascular safety was evaluated on the basis of an adjudicated
composite end point. In both studies and at both starting doses, peginesatide was non-
inferior to darbepoetin in increasing and maintaining Hb levels. The mean differences in the
Hb level with peginesatide as compared with darbepoetin in PEARL 1 were 0.03 g/dL (97.5 %
[CI]: -0.19 to 0.26) for the lower starting dose of peginesatide and 0.26 g/dL (97.5 % CI: 0.04
to 0.48) for the higher starting dose, and in PEARL 2 they were 0.14 g/dL (97.5 % CI: -0.09 to
0.36) and 0.31 g/dL (97.5 % CI: 0.08 to 0.54), respectively. The hazard ratio for the
cardiovascular safety end point was 1.32 (95 % CI: 0.97 to 1.81) for peginesatide relative to
darbepoetin, with higher incidences of death, unstable angina, and arrhythmia with
peginesatide. The authors concluded that the efficacy of peginesatide (administered monthly)
was similar to that of darbepoetin (administered every 2 weeks) in increasing and maintaining
hemoglobin levels. However, cardiovascular events and mortality were increased with
peginesatide in patients with chronic kidney disease who were not undergoing dialysis. They
stated that there is a need for additional data to clarify the benefit-risk profile of peginesatide
in this patient population.
In an editorial that accompanied the afore-mentioned study, Drueke (2013) stated that
“Peginesatide has been recently approved in the United States for patients undergoing
hemodialysis, but not for patients who are not receiving hemodialysis. Is there any advantage
of using peginesatide rather than the existing ESAs? Less frequent dosing may be an
advantage under certain circumstances. Peginesatide does not induce pure red-cell aplasia,
but antibody development against this compound, although infrequent, may reduce its
efficacy. As with any new class of drugs, prolonged experience and monitoring are
necessary. Another important issue is cost. At a time when the prescription of much
cheaper, biologically similar ESAs is steadily growing outside the United States, expensive
new drugs will be competitive only if proven to result in better patient outcomes. Such
outcomes remain to be demonstrated for peginesatide and other new types of ESAs that are
in development”.
In a review on “Guillain-Barre syndrome”, Yuki and Hartung (2012) states that “eculizumab,
erythropoietin, and fasudil, which have been used in the treatment of other, unrelated medical
conditions, have shown promise in animal models of the Guillain-Barre syndrome, but clinical
studies are lacking”.
In a review on “Mechanisms and management of retinopathy of prematurity”, Hartnett and
Penn (2012) stated that “Very-low-birth-weight infants are at high risk not only for retinopathy
of prematurity but also for subsequent neurodevelopmental impairment. Interest in
erythropoietin as a neuroprotective agent is increasing. When administered in preterm
infants, erythropoietin was associated with improved cognition in childhood. Laboratory
studies have shown that early administration of erythropoietin reduced phase 1
avascularization in both mouse and rat models of oxygen-induced retinopathy. However,
retrospective studies have shown an association between erythropoietin and severe oxygen-
induced retinopathy in preterm infants. Erythropoietin was also found to promote intravitreal
angiogenesis in a transgenic mouse model of oxygen-induced retinopathy. Some
investigators have proposed administering erythropoietin early in preterm infants to promote
physiologic retinal vascular development and attempt to reduce the risk of development of
stage 3 retinopathy of prematurity, but additional studies are needed to determine the window
of time for relatively safe administration”. The authors concluded that current therapies for
severe retinopathy of prematurity focuses on laser therapy as well as visual rehabilitation, and
Erythropoiesis Stimulating Agents Page 18 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
potential new treatment strategies include targets within oxidative pathways, erythropoietin,
and anti-vascular endothelial growth factor agents.
Moebus et al (2013) noted that the AGO-ETC trial compared 5-year relapse-free survival of
intense dose-dense (IDD) sequential chemotherapy with epirubicin (E), paclitaxel (T), and
cyclophosphamide (C) (IDD-ETC) every 2 weeks versus conventional scheduled
epirubicin/cyclophosphamide followed by paclitaxel (EC→T) (every 3 weeks) as adjuvant
treatment in high-risk breast cancer patients. These researchers evaluated the safety and
effectiveness of epoetin alfa in a second randomization of the IDD arm. A total of 1,284
patients were enrolled; 658 patients were randomly assigned to the IDD-ETC treatment
group. Within the IDD-ETC group, 324 patients were further randomly assigned to the
epoetin alfa group, and 319 were randomly assigned to the non- ESA control group. Primary
efficacy end-points included change in Hb level from baseline to Cycle 9 and the percentage
of subjects requiring red blood cell transfusion. Relapse-free survival, overall survival, and
intra-mammary relapse were secondary end-points estimated with Kaplan-Meier and Cox
regression methods. Except for the primary hypothesis, all statistical tests were 2-sided.
Epoetin alfa avoided the decrease in Hb level (no decrease in the epoetin alfa group versus -
2.20 g/dL change for the control group; p < 0.001) and statistically significantly reduced the
percentage of subjects requiring red blood cell transfusion (12.8 % versus 28.1 %; p <
0.0001). The incidence of thrombotic events was 7 % in the epoetin alfa arm versus 3 % in
the control arm. After a median follow-up of 62 months, epoetin alfa treatment did not affect
overall survival, relapse-free survival, or intra-mammary relapse. The authors concluded that
epoetin alfa resulted in improved Hb levels and decreased transfusions without an impact on
relapse-free or overall survival. However, epoetin alfa had an adverse effect, resulting in
increased thrombosis.
Kansagara et al (2013) evaluated the benefits and harms of treatments for anemia in adults
with heart disease. Data sources included MEDLINE, EMBASE, and Cochrane databases;
clinical trial registries; reference lists; and technical advisors. English-language trials of blood
transfusions, iron, or ESAs in adults with anemia and congestive heart failure or coronary
heart disease and observational studies of transfusion were selected for analysis. Data on
study design, population characteristics, Hb levels, and health outcomes were extracted.
Trials were assessed for quality. Low-strength evidence from 6 trials and 26 observational
studies suggested that liberal transfusion protocols do not improve short-term mortality rates
compared with less aggressive protocols (combined relative risk among trials, 0.94 [95 % CI:
0.61 to 1.42]; I2 = 16.8 %), although decreased mortality rates occurred in a small trial of
patients with the acute coronary syndrome (1.8 % versus 13.0 %; p = 0.032). Moderate-
strength evidence from 3 trials of intravenous iron found improved short-term exercise
tolerance and quality of life in patients with heart failure. Moderate- to high-strength evidence
from 17 trials of ESA therapy found they offered no consistent benefits, but their use may be
associated with harms, such as VTE. The authors concluded that higher transfusion
thresholds do not consistently improve mortality rates, but large trials are needed.
Intravenous iron may help to alleviate symptoms in patients with heart failure and iron
deficiency and also warrants further study. Moreover, they stated that ESAs do not seem to
benefit patients with mild-to-moderate anemia and heart disease and may be associated with
serious harms.
In a Cochrane review, Marti-Carvajal et al (2013) evaluated the clinical benefits and harms of
ESAs for anemia in rheumatoid arthritis. These investigators searched the Cochrane Central
Register of Controlled Trials (CENTRAL) in The Cochrane Library (issue 7 2012), Ovid
MEDLINE and Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations (1948 to August
Erythropoiesis Stimulating Agents Page 19 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
7, 2012), OVID EMBASE (1980 to August 7, 2012), LILACS (1982 to August 7, 2012), the
Clinical Trials Search Portal of the World Health Organization, reference lists of the retrieved
publications and review articles. They did not apply any language restrictions. These
researchers included RCTs in patients aged 16 years or over, with a diagnosis of rheumatoid
arthritis affected by anemia. They considered health-related quality of life, fatigue and safety
as the primary outcomes. Two authors independently performed trial selection, risk of bias
assessment, and data extraction. They estimated difference in means with 95 % CIs for
continuous outcomes. They estimated risk ratios with 95 % CIs for binary outcomes. These
investigators included 3 RCTs with a total of 133 participants. All trials compared human
recombinant erythropoietin (EPO), for different durations (8, 12 and 52 weeks), versus
placebo. All RCTs assessed health-related quality of life. All trials had high or unclear risk of
bias for most domains, and were sponsored by the pharmaceutical industry. Two trials
administered EPO by a subcutaneous route while the other used an intravenous route.
These researchers decided not to pool results from trials, due to inconsistencies in the
reporting of results. Health-related quality of life: subcutaneous EPO -- 1 trial with 70 patients
at 52 weeks showed a statistically significant difference in improvement of patient global
assessment (median and interquartile range 3.5 (1.0 to 6.0) compared with placebo 4.5 (2.0
to 7.5) (p = 0.027) on a VAS scale (0 to 10)). The other shorter-term trials (12 weeks with
subcutaneous EPO and 8 weeks with intravenous administration) did not find statistically
significant differences between treatment and control groups in health-related quality of life
outcomes. Change in Hb: both trials of subcutaneous EPO showed a statistically significant
difference in increasing Hb levels; (i) at 52 weeks (1 trial, 70 patients), intervention Hb level
(median of 134, interquartile range 110 to 158 g/L) compared with the placebo group level
(median of 112, interquartile range; 86 to 128 g/L) (p = 0.0001); (ii) at 12 weeks (1 trial, 24
patients) compared with placebo (difference in means of 8.00, 95 % CI: 7.43 to 8.57).
Intravenous EPO at 8 weeks showed no statistically significant difference in increasing
hematocrit level for EPO versus placebo (difference in means of 4.69, 95 % CI: -0.17 to 9.55;
p = 0.06). Information on withdrawals due to adverse events was not reported in 2 trials, and
1 trial found no serious adverse events leading to withdrawals. None of the trials reported
withdrawals due to high blood pressure, or to lack of efficacy or to fatigue. The authors
concluded that there are conflicting data for ESAs to increase quality of life and Hb level by
treating anemia in patients with rheumatoid arthritis. However, this conclusion was based on
RCTs with a high-risk of bias, and relies on trials assessing EPO. They stated that the safety
profile of EPO is unclear; and future trials assessing ESAs for anemia in rheumatoid arthritis
should be conducted by independent researchers and reported according to the CONSORT
statements.
Tran et al (2014) noted that ESAs are widely used in treating anemia associated with renal
failure. They are also now used peri-operatively to reduce the use of allogeneic blood
transfusions (ABTs) in patients undergoing surgery with anticipated high blood loss. Although
they can reduce the risks associated with ABT and improve quality of life, the use of ESAs is
still associated with adverse effects. These investigators performed a systematic review to
examine the current evidence for the safety and effectiveness of peri-operative ESAs use. A
search of PubMed and Medline databases has been performed using a combination of search
terms including erythropoietin, peri-operative, surgical, safety and efficacy. The authors
concluded that current evidence supported the use of peri-operative ESAs to reduce the need
for ABT. However, large studies assessing safety in anemic patients with chronic renal
disease have found adverse effects including cardiovascular, stroke and thromboembolic
events. However, whether these concerns can be conferred onto the surgical population
remains to be seen as the peri-operative dosing strategies have been more variable in timing,
Erythropoiesis Stimulating Agents Page 20 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
dose and duration in comparison with those used for chronic diseases. Moreover, they stated
that future research needs to address the questions of optimal dosing strategies in order to
maximize the positive effects and minimize adverse events.
Appendix
Specific Criteria for Erythropoietin and Darbepoietin Therapy:
I. Criteria for Initiation of Therapy:
A. For treatment of anemia associated with myelosuppressive anticancer
chemotherapy:
1. Erythropoiesis stimulating agents (ESAs) are considered medically
necessary where hemoglobin (Hgb) has fallen below 10g/dL and the
following criteria are met:
a. Anemia is secondary to myelosuppressive anticancer
chemotherapy for solid tumors, multiple myeloma, lymphoma and
lymphocytic leukemia; and
b. Adequate iron stores have been demonstrated by means of bone
marrow iron or serum ferrtin levels (greater than 100 ng/ml) or
serum transferrin saturation (TSAT greater than 20%) within the
prior 12 months (Note: For persons with iron deficiency, ESAs
may be initiated simultaneously with iron replacement), and
c. Member is exhibiting symptoms of anemia (such as fatigue,
weakness, shortness of breath, or lightheadedness) affecting their
ability to perform activities of daily living, or the
member exhibits angina, syncope, or tachycardia from the
anemia; and
d. ESAs intended to decrease the need for transfusions in
persons who will receive chemotherapy for a minimum of 2
months.
2. Providers must confirm compliance and participation in the REMS
program that has been implemented for ESA being used in cancer; and
3. The starting dose of ESAs are equal to the following, based upon FDA
labeling, or comparable fixed dosing schedules:
a. Erythropoietin: 150 units/kg 3 times per week, or 40,000 units
weekly in adults; 600 units/kg (maximum 40,000 units) weekly for
children.
b. Darbepoetin: 2.25 mcg/kg per week, or 500 mcg every 3 weeks.
B. For treatment of anemia associated with myelodysplastic syndrome, ESAs
are considered medically necessary where hemoglobin (Hgb) has fallend below
10g/dL, and the following criteria are met:
1. Adequate iron stores are demonstrated by means of bone marrow iron or
serum ferritin levels (greater than 100 ng/dl) or serum transferrin
Erythropoiesis Stimulating Agents Page 21 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
saturation (TSAT greater than 20%) within the past 12 months (Note: For
persons with iron deficiency, ESAs may be initiated simultaneously with
iron replacement), and
2. Member is exhibiting symptoms of anemia (such as fatigue, weakness,
shortness of breath, or lightheadedness) affecting their ability to perform
activities of daily living, or the member exhibits angina, syncope, or
tachycardia from the anemia; and
3. Bone marrow has less than 15% blasts, and
4. Member has required transfusion of 2 or fewer units of blood per month,
and
5. Endogenous serum erythropoietin (EPO) levels are less than or equal
to 500 IU/L.
A. For treatment of anemia associated chronic renal failure on dialysis:
1. ESAs are considered medically necessary where hemoglobin (Hgb) is
less than 10 g/dL, and the following criteria are met:
a. Adequate iron stores are demonstrated by means of bone marrow
iron or serum ferritin levels (greater than 100
ng/ml) or serum transferrin saturation (TSAT greater than 20%)
within the past 12 months (Note: For persons with iron deficiency
on dialysis, ESAs may be initiated simultaneously with iron
replacement); and
b. Member is exhibiting symptoms of anemia (such as fatigue,
weakness, shortness of breath, or lightheadedness) affecting their
ability to perform activities of daily living, or the
member exhibits angina, syncope, or tachycardia from the
anemia; and
2. The starting dose is equal to the following, based upon FDA labeling, or
comparable fixed dose schedules:
a. Erythropoietin: 50 to 100 units/kg body weight 3 times per week
for adults; 50 units/kg body weight for children.
b. Darbepoetin: 0.45 mcg/kg body weight once-weekly or 0.75
mcg/kg body weight every 2 weeks.
B. For treatment of anemia associated chronic renal failure not on dialysis:
1. ESAs are considered medically necessary where hemoglobin (Hgb) is
less than 10 g/dL, and the following criteria are met:
a. Member has chronic kidney failure (defined as creatinine
clearance less than 60 ml/min, or glomerular filtration rate (GFR)
less than 60 ml/min/1.73 m2);
and
b. Adequate iron stores are demonstrated by means of bone marrow
iron or serum ferritin levels (greater than 100
ng/dl) or serum transferrin saturation (TSAT greater than 20%)
Erythropoiesis Stimulating Agents Page 22 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
within the past 12 months (Note: For persons with iron deficiency
on dialysis, ESAs may be initiated simultaneously with iron
replacement); and
c. Member is exhibiting symptoms of anemia (such as fatigue,
weakness, shortness of breath, or lightheadedness) affecting their
ability to perform activities of daily living, or the
member exhibits angina, syncope, or tachycardia from the
anemia; and
d. The rate of hemoglobin decline indicates the likelihood of
requiring a red blood cell (RBC) transfusion; and
e. Reducing the risk of alloimmunization and/or other RBC
transfusion-related risks is a goal.
2. The starting dose is equal to the following, based upon FDA labeling, or
comparable fixed dose schedules:
a. Erythropoietin: 50 to 100 units/kg body weight 3 times per week
for adults; 50 units/kg body weight for children.
b. Darbepoetin: 0.45 mcg/kg body weight once-weekly or 0.75
mcg/kg body weight every 2 weeks.
C. For treatment of anemia related to zidovudine in HIV-infected persons, ESAs
are considered medically necessary where hemoglobin (Hgb) is less than 10
g/dL, and the following criteria are met:
1. Adequate iron stores are demonstrated by means of bone marrow iron or
serum ferritin levels (greater than 100 ng/ml) or serum iron
saturation (TSAT greater than 20%) within the past 12 months (Note: For
persons with iron deficiency on dialysis, ESAs may be initiated
simultaneously with iron replacement); and
2. Member is exhibiting symptoms of anemia (such as fatigue, weakness,
shortness of breath, or lightheadedness) affecting their ability to perform
activities of daily living, or the member exhibits angina, syncope, or
tachycardia from the anemia; and
3. Endogenous EPO level is less than or equal to 500 IU/L; and
4. Dose of zidovudine is less than or equal to 4200 mg/week.
D. For treatment of anemia due to chemotherapy (e.g., ribavirin) in persons with
hepatitis C, ESAs are considered medically necessary where the Hgb is less
than 10 g/dL and the following criteria are met:
1. Member is receiving interferon or pegylated interferon plus ribavirin; and
2. Adequate iron stores are demonstrated by means of bone marrow iron or
serum ferritin levels (greater than 100 ng/dl) or serum transferrin
saturation (TSAT greater than 20%) within the past 12 months (Note: For
persons with iron deficiency on dialysis, ESAs may be initiated
simultaneously with iron replacement); and
3. Member is exhibiting symptoms of anemia (such as fatigue, weakness,
shortness of breath, or lightheadedness) affecting their ability to perform
Erythropoiesis Stimulating Agents Page 23 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
activities of daily living, or the member exhibits angina, syncope, or
tachycardia from the anemia; and
4. Hgb remains below 10 g/dl despite reduction of dose or ribavirin (dose of
ribavirin can be decreased by 80 percent of target dose; daily ribavirin
dose should not be less than 800 mg).
E. For treatment of anemia of chronic disease other than cancer, ESAs
are considered medically necessary where Hgb is less than 10 g/dL and the
following criteria are met:
1. An underlying chronic disease has been identified; and
2. Adequate iron stores are demonstrated by means of bone marrow iron or
serum ferritin levels (greater than 100 ng/dl) or serum transferrin
saturation (TSAT greater than 20%) within the past 12 months (Note: For
persons with iron deficiency on dialysis, ESAs may be initiated
simultaneously with iron replacement); and
3. Member is exhibiting symptoms of anemia (such as fatigue, weakness,
shortness of breath, or lightheadedness) affecting their ability to perform
activities of daily living, or the member exhibits angina, syncope, or
tachycardia from the anemia.
F. For treatment of anemic members scheduled to undergo high-risk surgery at
increased risk of or intolerant to transfusions, ESAs are considered medically
necessary in persons with a Hgb less than 13 g/dL.
G. For treatment of anemia of prematurity, ESAs are considered medically
necessary when the member has either a birth weight of less than 1,500 grams
or a gestational age of less than 33 weeks (medically necessary duration of
therapy limited to 6 weeks).
H. For special circumstance members who will not or can not receive whole blood
or components as replacement for traumatic or surgical loss, ESAs are
considered medically necessary in persons with a Hgb less than 12 g/dL.
II. Criteria for continuation of chronic ESAs in persons with anemia due to
myelosuppressive anticancer chemotherapy:
A. The maintenance dose of ESAs are equal to the starting dose if: (i) the
hemoglobin remains below 10 g/dL 4 weeks after initiation of therapy; and (ii)
the rise in hemoglobin is greater than or equal to 1 g/dL;
B. Continued administration of ESAs are considered not medically necessary if
there is a rapid rise in hemoglobin greater than 1 g/dl over 2 weeks of treatment
unless the hemoglobin remains below or subsequently falls to less than 10
g/dL. Continuation and reinstitution of ESA therapy must include a dose
reduction of 25% from the previously administered dose.
C. For persons whose hemoglobin rises less than 1 g/dl compared to pretreatment
baseline over 4 weeks of treatment and whose hemoglobin level remains less
than 10 g/dL after the 4 weeks of treatment, the recommended FDA label
starting dose of ESAs may be increased once by 25%. Continued use of ESAs
are considered not medically necessary if the hemoglobin rises less than 1
g/dl compared to pretreatment baseline by 8 weeks of treatment.
Erythropoiesis Stimulating Agents Page 24 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
III. Criteria for continuation of chronic ESAs for chronic renal failure on dialysis:
A. ESAs should be administered with a Hgb range of 10 g/dL to 11 g/dL (Note:
maintenance at a higher Hgb level may be necessary for persons with acute
myocardial infarction, angina, orthostatic hypotension, living at an elevation of
greater than 6000 feet, or anemia with Hgb below 11 g/dL has significantly
interfered with activities of daily living).
B. For hemoglobin less than 10 g/dL, dose may be increased by up to 50 % over
the previously administered dose, until the hemoglobin is between 10 g/dL and
less than or equal to 11 g/dL. Dosage adjustments may be made as frequently
as twice monthly. Exception: If, after increasing the ESA dose, the hemoglobin
has risen more than 0.5 g/dL in the past 2 weeks or more than 1 g/dL in the
past 4 weeks, decrease dose by 25 % over the previously administered dose.
C. For hemoglobin greater than 11 g/dL and less than or equal to 14 g/dL, the
dose should be decreased by 10 % over the previously administered dose.
Dose decreases should be made twice-monthly until the hemoglobin is less
than or equal to 11 g/dL.
D. For hemoglobin greater than 14 g/dL and less than or equal to 15 g/dL, the
dose should be decreased by 25 % over the previously administered dose.
Dose decreases can be made twice-monthly or monthly until the hemoglobin
falls to less than 11 g/dL.
E. For hemoglobin greater than 15 g/dL, the dose of ESAs should be held and
should be restarted at 50 % of the previously administered dose when the
hemoglobin is less than or equal to 11 g/dL.
IV. Criteria for continuation of chronic ESAs for chronic renal failure not on dialysis:
A. If the hemoglobin level exceeds 10 g/dL, reduce or interrupt the dose of ESAs,
and use the lowest dose of ESAs sufficient to reduce the need for RBC
transfusions.
V. Criteria for continuation of chronic ESAs for other indications:
For persons who meet medical necessity criteria for ESAs, continued ESAs
are considered medically necessary for persons with a Hgb less than 11g/dL. (For
anemic members scheduled to undergo high-risk surgery, continued ESAs are
considered medically necessary where Hgb is less than 13 g/dL).
VI. Discontinuation criteria for ESAs:
A. For indications other than end-stage renal disease, continued ESAs
are considered not medically necessary if the member's Hgb has failed to rise
by 1 g/dL compared to pre-treatment baseline within 8 weeks of therapy despite
appropriate dose escalation.
B. Continued ESAs are considered not medically necessary for myelodysplastic
syndrome if transfusion requirements have been reduced by less than 50%
after 6 months of therapy.
C. ESAs for each course of chemotherapy for anemic persons with cancer or
hepatitis C includes the 8 weeks following the final dose of chemotherapy in a
Erythropoiesis Stimulating Agents Page 25 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
chemotherapy regimen.
VII. Underlying Causes of Anemia of Chronic Disease: The following conditions have been
associated with anemia of chronic disease (Weiss and Goodnough, 2005):
A. Infections (acute and chronic)
1. Bacterial
2. Fungal
3. Parasitic
4. Viral infections, including human immunodeficiency virus infection
B. Autoimmune
1. Inflammatory bowel disease
2. Rheumatoid arthritis
3. Sarcoidosis
4. Systemic lupus erythematosus and connective tissue diseases
5. Vasculitis
C. Cancer
1. Hematologic
2. Solid tumor
D. Chronic rejection after solid-organ transplantation
VIII. FDA-Approved Indications and Brands of Erythropoiesis-Stimulating Agents
Note: There is a lack of evidence that one brand of erythropoietin alpha (i.e., Procrit,
Epogen) is more effective than another brand. In addition, there is a lack of reliable
evidence that darbepoetin is more effective than erythropoietin alpha for darbepoetin's
labeled indications.
FDA-Approved Indications Brands of ESAs
Treatment of anemia of chronic renal failure Epogen, Omontys, Procrit,
Aranesp
Treatment of anemia in zidovudine-treated HIV-
infected patients
Epogen, Procrit
Treatment of anemia in cancer patients on
chemotherapy
Epogen, Procrit, Aranesp
Reduction of allogeneic blood transfusion in surgery
patients
Epogen, Procrit
Erythropoiesis Stimulating Agents Page 26 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
IX. Normal Reference Range of Serum Iron and Serum Ferritin:
A. Serum Iron:
Children: 50 to 120 µg/dL
Men: 65 to 176 µg/dL
Newborns: 100 to 250 µg/dL
Women: 50 to 170 µg/dL
Source: Slon, 2006.
B. Serum Ferritin:
Female: 12 to 150 ng/mL
Male: 12 to 300 ng/mL
Source: Gersten, 2009.
CPT Codes / HCPCS Codes / ICD-9 Codes
Erythropoietin or darbepoetin therapy:
Other CPT codes related to the CPB:
96401 - 96417
99601 - 99602
HCPCS codes covered if selection criteria are met:
J0881 Injection, darbepoetin alfa, 1 mcg (non-ESRD use)
J0882 Injection, darbepoetin alfa, 1 mcg (for ESRD on dialysis)
J0885 Injection, epoetin alfa, (for non-ESRD use), 1,000 units
J0886 Injection, epoetin alfa, 1000 units (for ESRD on dialysis)
Q4081 Injection, epoetin alfa, 100 units (for ESRD on dialysis)
S9537 Home therapy; hematopoietic hormone injection therapy (e.g.,
erythropoietin, G-CSF, GM-CSF); administrative services, professional
pharmacy services, care coordination, and all necessary supplies and
equipment (drugs and nursing visits coded separately), per diem
HCPCS codes not covered for indications listed in the CPB :
Modifier EB Erythropoetic stimulating agent (ESA) administered to treat anemia due
to anticancer radiotherapy
Other HCPC codes related to the CPB:
J9213 Injection, interferon, alfa-2a, recombinant, 3 million units
Erythropoiesis Stimulating Agents Page 27 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
J9214 Injection, interferon, alfa-2b, recombinant, 1 million units
S0145 Injection, pegylated interferon alfa-2a, 180 mcg per ml
S0148 Injection, pegylated interferon alfa-2B, 10 mcg
ICD-9 codes covered if selection criteria are met:
042 Human immunodeficiency virus [HIV] disease
079.53 Human immunodeficiency virus, type 2 [HIV-2]
140.0 - 204.92 Malignant neoplasm
238.72 - 238.75 Myelodysplastic syndrome
285.3 Antineoplastic chemotherapy induced anemia
285.21 - 285.29 Anemia of chronic disease [not covered for breast cancer]
585.1 - 585.9 Chronic kidney disease (CKD)
776.6 Anemia of prematurity
ICD-9 codes not covered for indications listed in the CPB (not all-inclusive):
205.00 - 208.92 Myeloid leukemia, monocytic leukemia, and other specified leukemia
238.71 Essential thrombocythemia
238.76 Myelofibrosis with myeloid metaplasia
272.7 Lipidoses [Gaucher's disease]
280.0 - 280.9 Iron deficiency anemias
281.1 - 281.2 Other vitamin B12 deficiency anemia
282.0 - 282.9 Hereditary hemolytic anemias
283.0 - 283.9 Acquired hemolytic anemias
284.0 - 284.9 Aplastic anemia and other bone marrow failure syndromes
285.1 Acute posthemorrhagic anemia
286.6 Defibrination syndrome
289.83 Myelofibrosis
295.00 - 295.95 Schizophrenic disorders
310.2 Postconcussion syndrome
337.00 - 337.9 Disorders of the autonomic nervous system
340 Multiple sclerosis
Erythropoiesis Stimulating Agents Page 28 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
348.1 Anoxic brain damage
357.0 Acute infective polyneuritis [Guillain-Barre syndrome]
362.20 - 362.29 Retinopathy of prematurity
410.00 - 414.9 Ischemic heart disease
427.89 Other specified cardiac dysrhythmias
428.0 - 428.9 Heart failure
433.00 - 434.91,
436 - 438.9
Occlusion and stenosis of precerebral arteries, cerebral arteries, acute,
but ill-defined, cerebrovascular disease, other and ill-defined,
cerebrovascular disease, and late effects of cerebrovascular disease
[except transient ischemic attacks]
584.5 - 584.9 Acute kidney failure
648.20 - 648.24 Anemia complicating pregnancy, childbirth, or the puerperium
737.30 - 737.39 Kyphoscoliosis and scoliosis
737.43 Scoliosis associated with other conditions
756.83 Ehlers-Danlos syndrome
772.4 Fetal and neonatal gastrointestinal hemorrhage
785.51 Cardiogenic shock
785.6 Enlargement of lymph nodes [Castleman's disease]
850.0 - 854.19 Intracranial injury
905.0 Late effect of fracture of skull and face bones
907.0 Late effect of intracranial injury without mention of skull fracture
990 Effects of radiation, unspecified
Other ICD-9 codes related to the CPB:
001.0 - 139.8 Infectious and parasitic diseases [acute and chronic viral, bacterial,
parasitic, and fungal]
230.0 - 234.9 Carcinoma in situ
401.0 - 405.99 Hypertensive disease
411.1 Intermediate coronary syndrome [unstable angina]
413.9 Other and unspecified angina pectoris
447.6 Arteritis, unspecified
447.7 Other specified disorders of arteries and arterioles
Erythropoiesis Stimulating Agents Page 29 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
458.0 Orthostatic hypotension
555.0 - 556.9 Regional enteritis and ulcerative colitis
564.1 Irritable bowel syndrome
585.1 - 585.9 Chronic kidney disease
710.0 Systemic lupus erythematosus
714.0 - 714.33 Rheumatoid arthritis
780.2 Syncope and collapse
780.4 Dizziness and giddiness [light-headedness]
780.79 Other malaise and fatigue
785.0 Tachycardia, unspecified
786.05 Shortness of breath
993.2 Other and unspecified effects of high altitude [living at an elevation of
greater than 6000 feet]
996.80 - 996.89 Complications of transplanted organ
E930.7 Adverse effects of antineoplastic antibiotics
E933.1 Adverse effects of antineoplastic and immunosuppressive drugs
V45.11 Renal dialysis status
V56.0 Encounter for extracorporeal dialysis
V56.8 Encounter for other dialysis
V58.11 - V58.12 Encounter for antineoplastic chemotherapy and immunotherapy
V62.6 Refusal of treatment for reasons of religion or conscience
Peginesatide (Omontys):
HCPCS codes covered if selection criteria are met:
J0890 Injection, Peginesatide 0.1 MG (for ESRD on dialysis)
ICD-9 codes covered if selection criteria are met:
285.21 Anemia in chronic kidney disease
Sodium Ferric Gluconate:
HCPCS codes covered if selection criteria are met:
J2916 Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg
Erythropoiesis Stimulating Agents Page 30 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
ICD-9 codes covered if selection criteria are met:
280.0 - 280.9 Iron deficiency anemias
Other ICD-9 codes related to the CPB:
V45.11 Renal dialysis status
The above policy is based on the following references:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Beusterien KM, Nissenson AR, Port FK, et al. The effects of recombinant human
erythropoietin on functional health and well-being in chronic dialysis patients. J Am
Soc Nephrol. 1996;7(5):763-773.
Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the
treatment of anemia associated with human immunodeficiency virus (HIV) infection
and zidovudine therapy. Overview of four clinical trials. Ann Int Med. 1992;117(9):739-
748.
Henry DH. Recombinant human erythropoietin treatment of anemic cancer patients.
Cancer Pract. 1996;4(4):180-184.
Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and
chemotherapy-induced anemia: Results of double-blind and open-label follow-up
studies. Semin Onc. 1994;21(2 Suppl 3):21-28.
Canadian Orthopedic Perioperative Erythropoietin Study Group. Effectiveness of
perioperative recombinant human erythropoietin in elective hip replacement. Lancet.
1993;341(8855):1227-1232.
Mittelman M, Lessin LS. Clinical application of recombinant erythropoietin in
myelodysplasia. Hematol Oncol Clin North Am. 1994;8(5):993-1009.
Phibbs RH. Potential for treatment of anemia of prematurity with recombinant human
erythropoietin. Curr Opin Pediatr. 1995;7(2):140-145.
Gallagher PG, Ehrenkranz RA. Erythropoietin therapy for anemia of prematurity. Clin
Perinatol. 1993;20(1):169-191.
United States Pharmacopeial Convention, Inc. (USPC). USP Dispensing Information.
Volume I -- Drug Information for the Health Care Professional. Rockville, MD:
Greenwood Village, CO: Micromedex; 2003.
American Society of Health-System Pharmacists, Inc. American Hospital Formulary
Service Drug Information 2003. Bethesda, MD: American Society of Health-System
Pharmacists; 2003.
Medical Economics, Inc. Physicians' Desk Reference. 57th Ed. Montvale, NJ: Medical
Economics; 2003.
Abernathy DR, Arnold GJ, Azarnoff D, et al., eds. 2003 Mosby's Drug Consult. St.
Louis, MO: Mosby-Year Book, Inc.; 2003.
Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage
renal disease with recombinant human erythropoietin: Results of a combined phase I
and II clinical trial. N Engl J Med. 1987;316:73-78.
Mohini R. Clinical efficacy of recombinant human erythropoietin in hemodialysis
patients. Semin Nephrol. 1989;9 Suppl 1:16-21.
Schwenk MH, Halstenson CE. Recombinant human erythropoietin. DICP. 1989;23(7-
8):528-536.
Erythropoiesis Stimulating Agents Page 31 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
McMullin MF, Hillmen P, Elder GE. Serum erythropoietin levels in paroxysmal
nocturnal hemoglobinuria: Implications for therapy. Br J Haematol. 1996;92:815-817.
Bourantas K. High-dose recombinant human erythropoietin and low-dose
corticosteroids for treatment of anemia in paroxysmal nocturnal hemoglobinuria. Acta
Haematol. 1994;91:62-65.
Nagel RL, Vichinsky E, Shah M, et al. Reticulocyte response in sickle cell anemia
treated with recombinant human erythropoietin: A double-blind study. Blood. 1993;81:9
-14.
Goldberg MA, Brugnara C, Dover GJ, et al. Hydroxyurea and erythropoietin therapy in
sickle cell anemia. Semin Oncol. 1992;19(3 Suppl 9):74-81.
El-Hazmi MA, Al-Momen A, Kandaswamy S, et al. On the use of
hydroxyurea/erythropoietin combination therapy for sickle cell disease. Acta Haematol.
1995;94:128-134.
Dover G. Charache S. Hydroxyurea induction of fetal hemoglobin synthesis in sickle-
cell disease. Semin Oncol. 1992;19(3 Suppl 9):61-66.
Marchi S, Cacchin E, Vallalta D, et al. Relief of pruritus and decreases in plasma
histamine concentrations during erythropoietin therapy in patients with uremia. N Engl
J Med. 1992;326:969-974.
Otten N. Economic evaluation of erythropoietin use in surgery. Technology Overview.
Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment
(CCOHTA); 1998.
Wild C, Jonas S. Erythropoietin in tumor anemia. An assessment [summary]. ITA-
Reports June 1/2000. ITA-Projektbericht 15. Vienna, Austria: Institute of Technology
Assessment (ITA); 2000.
Ibbotson T, Goa KL. Darbepoetin alfa. Drugs. 2001;61(14):2097-2104; discussion
2105-2106.
Nissenson AR. Novel erythropoiesis stimulating protein for managing the anemia of
chronic kidney disease. Am J Kidney Dis. 2001;38(6):1390-1397.
Aljama P, Bommer J, Canaud B, et al. Practical guidelines for the use of NESP in
treating renal anaemia. Nephrol Dial Transplant. 2001;16 Suppl 3:22-28.
Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis
stimulating protein (NESP). Nephrol Dial Transplant. 2001;16 Suppl 3:14-21.
Egrie JC, Browne JK. Development and characterization of novel erythropoiesis
stimulating protein (NESP). Nephrol Dial Transplant. 2001;16 Suppl 3:3-13.
Smith RE Jr, Jaiyesimi IA, Meza LA, et al. Novel erythropoiesis stimulating protein
(NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J
Cancer. 2001;84 Suppl 1:24-30.
Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis
stimulating protein (NESP) in cancer patients: Preliminary report. Br J Cancer. 2001;84
Suppl 1:11-16.
Egrie JC, Browne JK. Development and characterization of novel erythropoiesis
stimulating protein (NESP). Br J Cancer. 2001;84 Suppl 1:3-10.
Glaspy J. Introduction. Improving the standard of care in the management of cancer-
related anaemia: Focus on darbepoetin alfa, a novel erythropoiesis-stimulating protein.
Br J Cancer. 2001;84 Suppl 1:1-2.
Glaspy J, Jadeja JS, Justice G, et al. A dose-finding and safety study of novel
erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients
receiving multicycle chemotherapy. Br J Cancer. 2001;84 Suppl 1:17-23.
Erythropoiesis Stimulating Agents Page 32 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
Carr D, Goudas L, Lawrence D, et al. Management of cancer symptoms: pain,
depression, and fatigue. Evidence Report/Technology Assessment No. 61. Rockville,
MD: Agency for Healthcare Research and Quality (AHRQ); 2001.
Hudson JQ, Sameri RM. Darbepoetin alfa, a new therapy for the management of
anemia of chronic kidney disease. Pharmacotherapy. 2002;22(9 Pt 2):141S-149S.
Henry DH. Optimizing the treatment of anemia in cancer patients. The role of a new
erythropoietic agent. Oncology (Huntingt). 2002;16(10 Suppl 11):9-12.
Gergely AE, Lafarge P, Fouchard-Hubert I, Lunel-Fabiani F. Treatment of
ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.
Hepatology. 2002;35(5):1281-1282.
Talal AH, Weisz K, Hau T, et al. A preliminary study of erythropoietin for anemia
associated with ribavirin and interferon-alpha. Am J Gastroenterol. 2001;96(9):2802-
2804.
Dieterich DT. Treatment of hepatitis C and anemia in human immunodeficiency virus-
infected patients. J Infect Dis. 2002;185 Suppl 2:S128-S137.
Narayanan Menon KV, Poterucha JJ, et al. Treatment of posttransplantation
recurrence of hepatitis C with interferon and ribavirin: Lessons on tolerability and
efficacy. Liver Transpl. 2002;8(7):623-629.
Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
Darbepoetin alpha. Emerging Drug List No. 29. Ottawa, ON: CCOHTA; March 2002.
Aronson N, Piper M, Redding Flamm C, et al. Uses of epoetin for anemia in oncology.
Evidence Report/Technology Assessment 30. Rockville, MD: Agency for Healthcare
Research and Quality (AHRQ); 2001
Redding Flamm C, Aronson N, et al. Use of epoetin for anemia in chronic renal failure.
Evidence Report/Technology Assessment 21. Rockville, MD: Agency for Healthcare
Research, Quality (AHRQ); 2001.
Blumenauer B, Cranney A, Clinch J, Tugwell P. Quality of life in patients with
rheumatoid arthritis: Which drugs might make a difference? Pharmacoeconomics.
2003;21(13):927-940.
Cvetkovic RS, Goa KL. Darbepoetin alfa: In patients with chemotherapy-related
anaemia. Drugs. 2003;63(11):1067-1074; discussion 1075-1077.
Pajoumand M, Erstad BL, Camamo JM. Use of epoetin alfa in critically ill patients. Ann
Pharmacother. 2004;38(4):641-648.
Henry DH, Bowers P, Romano MT, Provenzano R. Epoetin alfa. Clinical evolution of a
pleiotropic cytokine. Arch Intern Med. 2004;164(3):262-276.
Carson JL. Should patients in intensive care units receive erythropoietin? JAMA. 2002;
11;288(22):2884-2886.
Corwin HL, Gettinger A, Pearl RG, et al. and the EPO Critical Care Trials Group.
Efficacy of recombinant human erythropoietin in critically ill patients: A randomized
controlled trial. JAMA. 2002;288(22):2827-2835.
Eckardt KU. Anaemia of critical illness-- implications for understanding and treating
rHuEPO resistance. Nephrol Dial Transplant. 2002;17 Suppl 5:48-55.
Darveau M, Notebaert E, Denault AY, Belisle S. Recombinant human erythropoietin
use in intensive care. Ann Pharmacother. 2002;36(6):1068-1074.
Corwin HL. Anemia in the critically ill: the role of erythropoietin. Semin Hematol.
2001;38(3 Suppl 7):24-32.
van Iperen CE, Gaillard CA, Kraaijenhagen RJ, et al. Response of erythropoiesis and
iron metabolism to recombinant human erythropoietin in intensive care unit patients.
Crit Care Med. 2000;28(8):2773-2778.
Erythropoiesis Stimulating Agents Page 33 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
Zimmerman JL. Use of blood products in sepsis: An evidence-based review. Crit Care
Med. 2004;32(11 Suppl):S542-S547.
Ehrenreich H, Timner W, Siren AL. A novel role for an established player: Anemia drug
erythropoietin for the treatment of cerebral hypoxia/ischemia. Transfus Apheresis Sci.
2004;31(1):39-44.
Ehrenreich H, Aust C, Krampe H, et al. Erythropoietin: Novel approaches to
neuroprotection in human brain disease. Metab Brain Dis. 2004;19(3-4):195-206.
Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer
patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-
controlled trial. Lancet. 2003;362(9392):1255-1260.
Boogaerts M, Mittelman M, Vaupel P. Beyond anaemia management: Evolving role of
erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia
models. Oncology. 2005;69 Suppl 2:22-30.
Jones M, Schenkel B, Just J. Epoetin alfa's effect on left ventricular hypertrophy and
subsequent mortality. Int J Cardiol. 2005;100(2):253-265.
Cody J, Daly C, Campbell M, et al. Frequency of administration of recombinant human
erythropoietin for anaemia of end-stage renal disease in dialysis patients. Cochrane
Database Syst Rev. 2005;(3):CD003895.
Strippoli GFM, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for
the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2006;
(4):CD003967.
Djulbegovic B. Erythropoietin use in oncology: A summary of the evidence and practice
guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue
Shield to set up the ASCO/ASH guidelines. Best Pract Res Clin Haematol. 2005;18
(3):455-466.
Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin
levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer
receiving first-line chemotherapy: A survival study. J Clin Oncol. 2005;23(25):5960-
5972.
Glaspy JA. Cancer patient survival and erythropoietin. J Natl Compr Canc Netw.
2005;3(6):796-804.
Danish Centre for Evaluation and Health Technology Assessment (DACEHTA).
Epoetin (EPO) for anaemic cancer patients. Executive Summary. Danish Health
Technology Assessment. Copenhagen, Denmark: DACEHTA; 2004;6(1).
Quirt I, Bramwell V, Charette M, Oliver T; Systemic Treatment Disease Site Group.
The role of erythropoietin in the management of cancer patients with non-hematologic
malignancies receiving chemotherapy. Cancer Care Ontario Practice Guidelines.
Toronto, ON: Cancer Care Ontario; March 2005. Available at:
http://www.cancercare.on.ca/pdf/pebc12-1f.pdf. Accessed March 9, 2006.
Brines ML,Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to
protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97:10526-
10531.
Wang L. Treatment of stroke with erythropoietin enhances neurogenesis and
angiogenesis and improves neurological function in rats. Stroke. 2004;35:1732-1737.
Siren AL. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and
metabolic stress. Proc Natl Acad Sci USA. 2001;98:4044-4409.
Ehrenreich H. Erythropoietin therapy for acute stroke is both safe and beneficial.
Molecul Med. 2002;8:495-505.
Erbayraktar S. Asialoerythropoietin is a nonerythropoietic cytokine with broad
neuroprotective activity in vivo. Proc Natl Acad Sci USA. 2003;100:6741-6746.
Erythropoiesis Stimulating Agents Page 34 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
Leist M. Derivatives of erythropoietin that are tissue protective but not erythropoietic.
Science. 2004;305:239-242.
Dodd J, Dare MR, Middleton P. Treatment for women with postpartum iron deficiency
anaemia. Cochrane Database Syst Rev. 2004;(4):CD004222.
Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic
renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev. 2005;
(3):CD003266.
Ross SD, Allen IE, Henry DH, et al. Clinical benefits and risks associated with epoetin
and darbepoetin in patients with chemotherapy-induced anemia: A systematic review
of the literature. Clin Therapeut. 2006;28(6):801-831.
Bath PMW, Sprigg N. Colony stimulating factors (including erythropoietin, granulocyte
colony stimulating factor and analogues) for stroke. Cochrane Database Syst Rev.
2007;(2):CD005207.
Martí-Carvajal AJ, Solà I. Treatment for anemia in people with AIDS. Cochrane
Database Syst Rev. 2007;(1):CD004476.
Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in
preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006;
(3):CD004863.
Aher S, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in
preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006;
(3):CD004868.
Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with
cancer. Cochrane Database Syst Rev. 2006;(3):CD003407.
Seidenfeld J, Piper M, Bohlius J, et al. Comparative effectiveness of epoetin and
darbepoetin for managing anemia in patients undergoing cancer treatment.
Comparative Effectiveness Review No. 3. AHRQ Pub. No. 06-EHC008-1. Rockville,
MD: Agency for Healthcare Research and Quality (AHRQ): May 2006. Available at:
http://effectivehealthcare.ahrq.gov/synthesize/reports/final.cfm. Accessed January 24,
2007.
Singh AK, Szczech L, Tang KL, et al.; CHOIR Investigators. Correction of anemia with
epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098.
Steinbrook R. Medicare and erythropoietin. N Engl J Med. 2007;356(1):4-6.
U.S. Food and Drug Administration (FDA). FDA Public Health Advisory. Epoetin alfa
(marketed as Procrit, Epogen); darbepoetin alfa (marketed as Aranesp). Rockville, MD:
FDA; November 16, 2006. Available at
http://www.fda.gov/cder/drug/advisory/RHE.htm. Accessed January 23, 2007.
Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: Evidence
-based clinical practice guidelines of the American Society of Clinical Oncology and the
American Society of Hematology. J Clin Oncol. 2002;20(19):4083-4107.
National Comprehensive Cancer Network (NCCN). Cancer- and treatment-related
anemia. NCCN Clinical Practice Guidelines in Oncology v2.2006. Jenkintown, PA:
NCCN; 2006.
Hedenus M, Vansteenkiste J, Kotasek D, et al. Darbepoetin alfa for the treatment of
chemotherapy-induced anemia: Disease progression and survival analysis from four
randomized, double-blind, placebo-controlled trials. J Clin Oncol. 2005;23(28):6941-
6948.
Jose Aguado Romeo M, Villegas Portero R. Use of recombinant human erythropoietin
in orthopedic surgery [summary]. Seville, Spain: Andalusian Agency for Health
Technology Assessment (AETSA); 2007.
Erythropoiesis Stimulating Agents Page 35 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
Craig J, Brown H, Eastgate J, et al. The use of epoetin alfa before orthopaedic surgery
in patients with mild anaemia. Health Technology Assessment Report 8. Glasgow,
Scotland; NHS Quality Improvement Scotland (NHS QIS); 2006.
Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of
epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer,
especially that attributable to cancer treatment. Health Technol Assess. 2007;11(13):1-
220.
Martí-Carvajal AJ, Solà I. Treatment for anemia in people with AIDS. Cochrane
Database Syst Rev. 2007;(1):CD004776.
Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial
of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin
Oncol. 2007; [Epub ahead of print].
U.S. Food and Drug Administration (FDA). FDA strengthens safety information for
erythropoiesis-stimulating agents (ESAs). FDA News. P07-40. Rockville, MD: FDA;
March 9, 2007.
Peck P. Black box warning ordered for Aranesp, Epogen, and Procrit. MedPage
Today, March 9, 2007.
National Comprehensive Cancer Network (NCCN). NCCN updates cancer- and
treatment-related anemia guidelines. NCCN News. Jenkintown, PA: NCCN; March 5,
2007.
National Institute for Health and Clinical Excellence (NICE). Epoetin alfa, epoetin beta,
and darbepoetin alfa for cancer treatment-induced anaemia. Final Appraisal
Determination. London, UK: NICE; February 2008.
Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin
concentrations in anaemic patients with chronic kidney disease treated with
erythropoietin: A meta-analysis. Lancet. 2007;369(9559):381-388.
Centers for Medicare and Medicaid Services (CMS). Coverage decision memorandum
for use of erythropoiesis stimulating agents in cancer and related neoplastic
conditions. CAG #00383N. Baltimore, MD: CMS; July 30, 2007.
Centers for Medicare and Medicaid Services (CMS). Monitoring of erythropoietin
stimulating agents for beneficiaries with end stage renal disease. Medicare Coverage
Database. Baltimore, MD: CMS; July 20, 2007.
Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic
anemia (SAA): A prospective comparison of four different regimens. Exp Hematol.
2006;34(7):826-831.
Ross SD, Allen IE, Probst CA, et al. Efficacy and safety of erythropoiesis-stimulating
proteins in myelodysplastic syndrome: A systematic review and meta-analysis.
Oncologist. 2007;12(10):1264-1273.
Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352
(10):1011-1023.
Rizzo JD, Somerfield MR, Hagerty KL, et al.; American Society of Clinical Oncology;
American Society of Hematology. Use of epoetin and darbepoetin in patients with
cancer: 2007 American Society of Clinical Oncology/American Society of Hematology
clinical practice guideline update. J Clin Oncol. 2008;26(1):132-149.
Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality
associated with erythropoietin and darbepoetin administration for the treatment of
cancer-associated anemia. JAMA. 2008;299(8):914-942.
Minton O, Stone P, Richardson A, et al. Drug therapy for the management of cancer
related fatigue. Cochrane Database Syst Rev. 2008;(1):CD006704.
Erythropoiesis Stimulating Agents Page 36 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
Gersten T. Ferritin. MedlinePlus Medical Encyclopedia. Bethesda, MD: National
Library of Medicine; updated January 12, 2009. Available at:
http://www.nlm.nih.gov/medlineplus/ency/article/003490.htm. Accessed March 30,
2009.
Slon S. Serum ferritin. Medical Lab Tests. Chicago, IL: University of Illinois at Chicago;
2006. Available at: http://uimc.discoveryhospital.com/main.php?t=enc&id=1456.
Accessed March 30, 2009.
Ghali JK, Anand IS, Abraham WT, et al.; Study of Anemia in Heart Failure Trial
(STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients
with symptomatic heart failure and anemia. Circulation. 2008;117(4):526-535.
Tonelli M, Klarenbach S, Wiebe N, et al. Erythropoiesis-stimulating agents for anemia
of chronic kidney disease: Systematic review and economic evaluation. HTA Issue
106. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH);
March 2008.
Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia
in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a
phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol.
2008;26(7):1040-1050.
Novak JE, Szczech LA. Triumph and tragedy: Anemia management in chronic kidney
disease. Curr Opin Nephrol Hypertens. 2008;17(6):580-588.
Dodd J, Dare MR, Middleton P. Treatment for women with postpartum iron deficiency
anaemia. Cochrane Database Syst Rev. 2004;(4):CD004222.
Breymann C, Visca E, Huch R, Huch A. Efficacy and safety of intravenously
administered iron sucrose with and without adjuvant recombinant human erythropoietin
for the treatment of resistant iron-deficiency anemia during pregnancy. Am J Obstet
Gynecol. 2001;184:662–667.
Wagstrom E, Akesson A, Van Rooijen M, et al. Erythropoietin and intravenous iron
therapy in postpartum anaemia. Acta Obstet Gynecol Scand. 2007;86: 957–962.
American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin
No. 95: Anemia in pregnancy. Obstet Gynecol. 2008;112(1):201-207.
Tonelli M, Lloyd A, Lee H, et al. Erythropoiesis-stimulating agents for anemia of cancer
or of chemotherapy: Systematic review and economic evaluation. Technology Report
No. 119. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health
(CADTH); April 2009.
Devon KM, McLeod RS. Pre and peri-operative erythropoeitin for reducing allogeneic
blood transfusions in colorectal cancer surgery. Cochrane Database Syst Rev. 2009;
(1):CD007148.
Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or darbepoetin for patients with
cancer - meta-analysis based on individual patient data. Cochrane Database Syst Rev.
2009:(3):CD007303.
Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis -
stimulating agents and mortality in patients with cancer: A meta-analysis of
randomised trials. Lancet. 2009;373:1532-1542.
Lambin P, Ramaekers BLT, van Mastrigt GAPG, et al. Erythropoietin as an adjuvant
treatment with (chemo) radiation therapy for head and neck cancer. Cochrane
Database Syst Rev. 2009;(3):CD006158.
Ngo K, Kotecha D, Walters JAE, et al. Erythropoiesis-stimulating agents for anaemia in
chronic heart failure patients. Cochrane Database Syst Rev. 2010;(1):CD007613.
Erythropoiesis Stimulating Agents Page 37 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
Drüeke TB, Locatelli F, Clyne N, et al; CREATE Investigators. Normalization of
hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med.
2006;355(20):2071-2084.
Pfeffer MA, Burdmann EA, Chen CY, et al; TREAT Investigators. A trial of darbepoetin
alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-
2032.
Marsden PA. Treatment of anemia in chronic kidney disease--strategies based on
evidence. N Engl J Med. 2009;361(21):2089-2090.
Ehrenreich H, Weissenborn K, Prange H, et al; EPO Stroke Trial Group. Recombinant
human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40
(12):e647-e656.
Talving P, Lustenberger T, Kobayashi L, et al. Erythropoiesis stimulating agent
administration improves survival after severe traumatic brain injury: A matched case
control study. Ann Surg. 2010;251(1):1-4.
Velmahos GC. Erythropoiesis and the mystery of an unexplained survival benefit. Ann
Surg. 2010;251(1):5.
Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents --
time for a reevaluation. N Engl J Med. 2010;362(3):189-192.
Springborg JB, Møller C, Gideon P, et al. Erythropoietin in patients with aneurysmal
subarachnoid haemorrhage: A double blind randomised clinical trial. Acta Neurochir
(Wien). 2007;149(11):1089-1101; discussion 1101.
Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in
chronic progressive multiple sclerosis. Brain. 2007;130(Pt 10):2577-2588.
Endre ZH, Walker RJ, Pickering JW, et al. Early intervention with erythropoietin does
not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int.
2010;77(11):1020-1030.
Beohar N, Rapp J, Pandya S, Losordo DW. Rebuilding the damaged heart: The
potential of cytokines and growth factors in the treatment of ischemic heart disease. J
Am Coll Cardiol. 2010;56(16):1287-1297.
Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: Erythropoiesis-
stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153
(1):23-33.
Weiner DE, Miskulin DC. Anemia management in chronic kidney disease: Bursting the
hemoglobin bubble. Ann Intern Med. 2010;153(1):53-55.
Rizzo JD, Brouwers M, Hurley P, et al; American Society of Clinical Oncology;
American Society of Hematology. American Society of Clinical Oncology/American
Society of Hematology clinical practice guideline update on the use of epoetin and
darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28(33):4996-5010.
U.S. Food and Drug Administration (FDA). FDA modifies dosing recommendations for
erythropoiesis-stimulating agents. Cites increased risk of cardiovascular events when
used to treat chronic kidney disease. FDA News Release. Rockville, MD: FDA; June
24, 2011.
Doss S, Schiller B. Peginesatide: A potential erythropoiesis stimulating agent for the
treatment of anemia of chronic renal failure. Nephrol Nurs J. 2010;37(6):617-626.
Endre ZH, Walker RJ, Pickering JW, et al. Early intervention with erythropoietin does
not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int.
2010;77(11):1020-1030.
Santos FP, Alvarado Y, Kantarjian H, et al. Long-term prognostic impact of the use of
erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic
phase treated with imatinib. Cancer. 2011;117(5):982-991.
Erythropoiesis Stimulating Agents Page 38 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
Kotecha D, Ngo K, Walters JA, et al. Erythropoietin as a treatment of anemia in heart
failure: Systematic review of randomized trials. Am Heart J. 2011;161(5):822-831.
Lipsic E, van der Meer P, van Veldhuisen DJ. Erythropoiesis-stimulating agents and
heart failure. Cardiovasc Ther. 2011;29(4):e52-e59.
Santilli G, Tarantini L, Baio P, Senni M. Diagnosis and treatment of anemia in heart
failure patients. G Ital Cardiol (Rome). 2011;12(5):319-326.
Najjar SS, Rao SV, Melloni C, et al; REVEAL Investigators. Intravenous erythropoietin
in patients with ST-segment elevation myocardial infarction: REVEAL: A randomized
controlled trial. JAMA. 2011;305(18):1863-1872.
Bhatt DL. Evaluation of agents to reduce infarct size: It can be quite REVEALing.
JAMA. 2011;305(18):1908-1909.
Macdougall IC, Wiecek A, Tucker B, et al. Dose-finding study of peginesatide for
anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol. 2011;6
(11):2579-2586.
U.S. Food and Drug Administration. FDA approves Omontys to treat anemia in adult
patients on dialysis. March 27, 2012. FDA: Silver Spring, MD. Available at:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm297464.htm.
Accessed May 1, 2012.
Fishbane S, Schiller B, Locatelli F, et al; EMERALD Study Groups. Peginesatide in
patients with anemia undergoing hemodialysis. N Engl J Med. 2013;368(4):307-319.
Macdougall IC, Provenzano R, Sharma A, et al; PEARL Study Groups. Peginesatide
for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med.
2013;368(4):320-332.
Drueke TB. Anemia treatment in patients with chronic kidney disease. N Engl J Med.
2013;368(4):387-389.
Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012;366(24):2294-2304.
Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N
Engl J Med. 2012;367(26):2515-2526.
Food and Drug Administration. FDA alerts health care providers of recall of anemia
drug Omontys. FDA: Silver Spring, MD. February 24, 2013. Available at:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340899.htm?
source=govdelivery. Accessed February 26, 2013.
Moebus V, Jackisch C, Schneeweiss A, et al; AGO Breast Study Group. Adding
epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer:
Randomized clinical trial. J Natl Cancer Inst. 2013;105(14):1018-1026.
Kansagara D, Dyer E, Englander H, et al. Treatment of anemia in patients with heart
disease: A systematic review. Ann Intern Med. 2013;159(11):746-757.
Marti-Carvajal AJ, Agreda-Perez LH, Sola I, Simancas-Racines D. Erythropoiesis-
stimulating agents for anemia in rheumatoid arthritis. Cochrane Database Syst Rev.
2013;2:CD000332.
Tran DH, Wong GT, Chee YE, Irwin MG. Effectiveness and safety of erythropoiesis-
stimulating agent use in the perioperative period. Expert Opin Biol Ther. 2014;14(1):51
-61.
Erythropoiesis Stimulating Agents Page 39 of 39
http://qawww.aetna.com/cpb/medical/data/100_199/0195_draft.html 11/03/2014
Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan
benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial,
general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care
services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in
private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible
for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to
change.
CPT only copyright 2008 American Medical Association. All Rights Reserved.